U.S. patent application number 12/485612 was filed with the patent office on 2009-10-08 for nociceptin analogs.
This patent application is currently assigned to Purdue Pharma L.P.. Invention is credited to Zhengming Chen, Parviz Gharagozloo, R. Richard Goehring, Donald Kyle, Sam Victory, John Whitehead.
Application Number | 20090253727 12/485612 |
Document ID | / |
Family ID | 26962736 |
Filed Date | 2009-10-08 |
United States Patent
Application |
20090253727 |
Kind Code |
A1 |
Goehring; R. Richard ; et
al. |
October 8, 2009 |
NOCICEPTIN ANALOGS
Abstract
A compound of the having the general formula (I) or general
formula (II): ##STR00001## wherein Z, A, B, C, R.sub.1, R.sub.2, Q,
W, and n are as described herein.
Inventors: |
Goehring; R. Richard;
(Pipersville, PA) ; Chen; Zhengming; (Belle Mead,
NJ) ; Whitehead; John; (Newtown, PA) ;
Gharagozloo; Parviz; (Pennington, NJ) ; Victory;
Sam; (Newtown, PA) ; Kyle; Donald; (Newtown,
PA) |
Correspondence
Address: |
PURDUE PHARMA, LP
201 TRESSER BOULEVARD, ONE STAMFORD FORUM
STAMFORD
CT
06901
US
|
Assignee: |
Purdue Pharma L.P.
Stamford
CT
|
Family ID: |
26962736 |
Appl. No.: |
12/485612 |
Filed: |
June 16, 2009 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
11069728 |
Mar 1, 2005 |
7563809 |
|
|
12485612 |
|
|
|
|
Current U.S.
Class: |
514/278 ;
514/312; 546/15; 546/158 |
Current CPC
Class: |
C07D 401/04 20130101;
C07D 417/04 20130101; A61P 25/00 20180101; A61P 25/04 20180101;
A61P 43/00 20180101; A61P 37/08 20180101; A61P 29/00 20180101 |
Class at
Publication: |
514/278 ;
546/158; 546/15; 514/312 |
International
Class: |
C07D 401/04 20060101
C07D401/04; A61K 31/4545 20060101 A61K031/4545; A61P 29/00 20060101
A61P029/00 |
Claims
1-32. (canceled)
33. A compound of the formula (II): ##STR00018## wherein W is
hydrogen, C.sub.1-10 alkyl, C.sub.3-12 cycloalkyl, C.sub.3-12
cycloalkylC.sub.1-4alkyl-, C.sub.1-10 alkoxy, C.sub.3-12
cycloalkoxy-, C.sub.1-10 alkyl substituted with 1-3 halogen,
C.sub.3-12 cycloalkyl substituted with 1-3, halogen, C.sub.3-12
cycloalkylC.sub.1-4alkyl-substituted with 1-3 halogen, C.sub.1-10
alkoxy substituted with 1-3 halogen, C.sub.3-12 cycloalkoxy-
substituted with 1-3 halogen, --COOV.sub.1, --C.sub.1-4COOV.sub.1,
--CH.sub.2OH, --SO.sub.2N(V.sub.1).sub.2, hydroxyC.sub.1-10alkyl-,
hydroxyC.sub.3-10cycloalkyl-, cyanoC.sub.1-10alkyl-,
cyanoC.sub.3-10cycloalkyl-, --CON(V.sub.1).sub.2,
NH.sub.2SO.sub.2C.sub.1-4alkyl-, NH.sub.2SOC.sub.1-4alkyl-,
sulfonylaminoC.sub.1-10alkyl-, diaminoalkyl-,
-sulfonylC.sub.1-4alkyl, a 6-membered heterocyclic ring, a
6-membered heteroaromatic ring, a 6-membered
heterocyclicC.sub.1-4alkyl-, a 6-membered
heteroaromaticC.sub.1-4alkyl-, a 6-membered aromatic ring, a
6-membered aromaticC.sub.1-4 alkyl-, a 5-membered heterocyclic ring
optionally substituted with an oxo or thio, a 5-membered
heteroaromatic ring, a 5-membered heterocyclicC.sub.1-4alkyl-
optionally substituted with an oxo or thio, a 5-membered
heteroaromaticC.sub.1-4alkyl-, --C.sub.1-5(.dbd.O)W.sub.1,
--C.sub.0-5(.dbd.NH)W.sub.1, --C.sub.1-5NHC(.dbd.O)W.sub.1,
--C.sub.1-5NHS(.dbd.O).sub.2W.sub.1, --C.sub.1-5NHS(.dbd.O)W.sub.1,
wherein W.sub.1 is hydrogen, C.sub.1-10 alkyl, C.sub.3-12
cycloalkyl, C.sub.1-10alkoxy, C.sub.3-12 cycloalkoxy, --CH.sub.2OH,
amino, C.sub.1-4alkylamino-, diC.sub.1-4alkylamino-, or a
5-membered heteroaromatic ring optionally substituted with 1-3
lower alkyl; wherein each V.sub.1 is independently selected from 1,
C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, benzyl and phenyl; Q is a 6
membered aromatic group; n is an integer from 0 to 3, A, B and C
are independently hydrogen, C.sub.1-10 alkyl, C.sub.3-12
cycloalkyl, C.sub.1-10alkoxy, C.sub.3-12 cycloalkoxy, --CH.sub.2OH,
--NHSO.sub.2, hydroxyC.sub.1-10alkyl-, aminocarbonyl-,
C.sub.1-4alkylaminocarbonyl-, diC.sub.1-4alkylaminocarbonyl-,
acylamino-, acylaminoalkyl-, amide, sulfonylaminoC.sub.1-10alkyl-,
or A-B can together form a C.sub.2-6 bridge, or B-C can together
form a C.sub.3-7 bridge, or A-C can together form a C.sub.1-5
bridge; Z is selected from the group consisting of a bond, straight
or branched C.sub.1-6 alkylene, --NH--, --CH.sub.2O--,
--CH.sub.2NH--, --CH.sub.2N(CH.sub.3)--, --NHCH.sub.2--,
--CH.sub.2CONH--, --NHCH.sub.2CO--, --CH.sub.2CO--, --COCH.sub.2--,
--CH.sub.2COCH.sub.2--, --CH(CH.sub.3)--, --CH.dbd., --O-- and
--HC.dbd.CH--, wherein the carbon and/or nitrogen atoms are
unsubstituted or substituted with one or more lower alkyl, hydroxy,
halo or alkoxy group; R.sub.1 is selected from the group consisting
of hydrogen, C.sub.1-10alkyl, C.sub.3-12cycloalkyl,
C.sub.2-10alkenyl, amino, C.sub.1-10alkylamino-,
C.sub.3-12cycloalkylamino-, --COOV.sub.1, --C.sub.1-4COOV.sub.1,
cyano, cyanoC.sub.1-10alkyl-, cyanoC.sub.3-10cycloalkyl-,
NH.sub.2SO.sub.2--, NH.sub.2SO.sub.2C.sub.1-4alkyl-,
NH.sub.2SOC.sub.1-4alkyl-, aminocarbonyl-,
C.sub.1-4alkylaminocarbonyl-, diC.sub.1-4alkylaminocarbonyl-,
benzyl, C.sub.3-12 cycloalkenyl-, a monocyclic, bicyclic or
tricyclic aryl or heteroaryl ring, a hetero-monocyclic ring, a
hetero-bicyclic ring system, and a spiro ring system of the formula
(III): ##STR00019## wherein X.sub.1 and X.sub.2 are independently
selected from the group consisting of NH, O, S and CH.sub.2;
wherein said allyl, cycloalkyl, alkenyl, C.sub.1-10alkylamino-,
C.sub.3-12cycloalkylamino-, or benzyl of R.sub.1 is optionally
substituted with 1-3 substituents selected from the group
consisting of halogen, hydroxy, C.sub.1-10 alkyl, C.sub.1-10
alkoxy, nitro, trifluoromethyl-, cyano, --COOV.sub.1,
--C.sub.1-4COOV.sub.1, cyanoC.sub.1-10alkyl-,
--C.sub.1-5(.dbd.O)W.sub.1, --C.sub.1-5NHS(.dbd.O).sub.2W.sub.1,
--C.sub.1-5NHS(.dbd.O)W.sub.1, a 5-membered
heteroaromaticC.sub.0-4alkyl-, phenyl, benzyl, benzyloxy, said
phenyl, benzyl, and benzyloxy optionally being substituted with 1-3
substituents selected from the group consisting of halogen,
C.sub.1-10 alkyl-, C.sub.1-10 alkoxy-, and cyano; and wherein said
C.sub.3-12 cycloalkyl, C.sub.3-12 cycloalkenyl, monocyclic,
bicyclic or tricyclic aryl, heteroaryl ring, hetero-monocyclic
ring, hetero-bicyclic ring system, or spiro ring system of the
formula (III) is optionally substituted with 1-3 substituents
selected from the group consisting of halogen, C.sub.1-10 alkyl,
C.sub.1-10 alkoxy, nitro, trifluoromethyl-, phenyl, benzyl,
phenyloxy and benzyloxy, wherein said phenyl, benzyl, phenyloxy or
benzyloxy is optionally substituted with 1-3 substituents selected
from the group consisting of halogen, C.sub.1-10 alkyl, C.sub.1-10
alkoxy, and cyano; R.sub.2 is selected from the group consisting of
hydrogen, C.sub.1-10 alkyl, C.sub.3-12 cycloalkyl and halogen, said
alkyl or cycloalkyl optionally substituted with an oxo, amino,
alkylamino or dialkylamino group; or a pharmaceutically acceptable
salt thereof or solvate thereof.
34. (canceled)
35. The compound of claim 33, wherein W is selected from the group
consisting of --CH.sub.2C(.dbd.O)NH.sub.2, --C(NH)NH.sub.2,
pyridylmethyl, cyclopentyl, cyclohexyl, furanylmethyl,
--C(O)CH.sub.3, --CH.sub.2CH.sub.2NHC.dbd.OCH.sub.3,
--SO.sub.2CH.sub.3, CH.sub.2CH.sub.2NHSO.sub.2CH.sub.3,
furanylcarbonyl-, methylpyrrolylcarbonyl-, diazolecarbonyl-,
azolemethyl-, trifluoroethyl-, hydroxyethyl-, cyano methyl-,
oxo-oxazolemethyl-, and diazolemethyl-.
36. The compound of claim 33, wherein ZR.sub.1 is selected from the
group consisting of cyclohexylethyl-, cyclohexylmethyl-,
cyclopentylmethyl-, dimethylcyclohexylmethyl-, phenylethyl-,
pyrrolyltrifluoroethyl-, thienyltrifluoroethyl-, pyridylethyl-,
cyclopentyl-, cyclohexyl-, methoxycyclohexyl-, tetrahydropyranyl-,
propylpiperidinyl-, indolylmethyl-, pyrazoylpentyl-,
thiazolylethyl-, phenyltrifluoroethyl-, hydroxyhexyl-,
methoxyhexyl-, isopropoxybutyl-, hexyl-, and oxocanylpropyl-.
37. The compound of claim 33, wherein at least one of ZR.sub.1 or W
is selected from the group consisting of CH.sub.2COOV.sub.1,
tetrazolylmethyl-, cyanomethyl-, NH.sub.2SO.sub.2methyl-,
NH.sub.2SOmethyl-, aminocarbonylmethyl-,
C.sub.1-4alKylaminocarbonylmethyl-, and
diC.sub.1-4alkylaminocarbonylmethyl-.
38. The compound of claim 33, wherein ZR.sub.1 is 3,3
diphenylpropyl optionally substituted at the 3 carbon of the propyl
with --COOH, --COOV.sub.1, tetrazolylC.sub.0-4alkyl-, cyano-,
aminocarbonyl-, C.sub.1-4alkylaminocarbonyl-, or
diC.sub.1-4alkylaminocarbonyl-.
39. A compound of the formula (IIA): ##STR00020## wherein n is an
integer from 0 to 3; Z is selected from the group consisting of a
bond, --CH.sub.2--, --NH--, --CH.sub.2O--, --CH.sub.2CH.sub.2--,
--CH.sub.2NH--, --CH.sub.2N(CH.sub.3)--, --NHCH.sub.2--,
--CH.sub.2CONH--, --NHCH.sub.2CO--, --CH.sub.2CO--, --COCH.sub.2--,
--CH.sub.2COCH.sub.2--, --CH(CH.sub.3)--, --CH.dbd., and
--HC.dbd.CH--, wherein the carbon and/or nitrogen atoms are
unsubstituted or substituted with a lower alkyl, halogen, hydroxy
or alkoxy group; R.sub.1 is selected from the group consisting of
hydrogen, C.sub.1-10alkyl, C.sub.3-12cycloalkyl, C.sub.2-10alkenyl,
amino, C.sub.1-10alkylamino, C.sub.3-12cycloalkylamino, benzyl,
C.sub.3-12 cycloalkenyl, a monocyclic, bicyclic or tricyclic aryl
or heteroaryl ring, a hetero-monocyclic ring, a hetero-bicyclic
ring system, and a spiro ring system of the formula (III):
##STR00021## wherein X.sub.1 and X.sub.2 are independently selected
from the group consisting of NH, O, S and CH.sub.2; wherein said
alkyl, cycloalkyl, alkenyl, C.sub.1-10 alkylamino,
C.sub.3-12cycloalkylamino, or benzyl is optionally substituted with
1-3 substituents selected from the group consisting of halogen,
C.sub.1-10 alkyl, C.sub.1-10 alkoxy, nitro, trifluoromethyl, cyano,
phenyl, benzyl, benzyloxy, said phenyl, benzyl, and benzyloxy
optionally being substituted with 1-3 substituents selected from
the group consisting of halogen, C.sub.1-10 alkyl, C.sub.1-10
alkoxy, and cyano; wherein said C.sub.3-12 cycloalkyl, C.sub.3-12
cycloalkenyl, monocyclic, bicyclic or tricyclic aryl, heteroaryl
ring, hetero-monocyclic ring, hetero-bicyclic ring system, and
spiro ring system of the formula (II) are optionally substituted
with 1-3 substituents selected from the group consisting of
halogen, C.sub.1-10 alkyl, C.sub.1-10 alkoxy, nitro,
trifluoromethyl, phenyl, benzyl, phenyloxy and benzyloxy, wherein
said phenyl, benzyl, phenyloxy and benzyloxy are optionally
substituted with 1-3 substituents selected from the group
consisting of halogen, C.sub.1-10 alkyl, C.sub.1-10 alkoxy, and
cyano; R.sub.2 is selected from the group consisting of hydrogen,
C.sub.1-10 alkyl, C.sub.3-12 cycloalkyl and halogen, said alkyl
optionally substituted with an oxo group; or a pharmaceutically
acceptable salt thereof.
40. A compound of claim 39, wherein R.sub.1 is alkyl selected from
the group consisting; of methyl, ethyl, propyl, butyl, pentyl and
hexyl.
41. A compound of claim 39, wherein R.sub.1 is cycloalkyl selected
from the group consisting of cyclohexyl, cycloheptyl, cyclooctyl,
cyclononyl, cyclodecyl, and norbornyl.
42. A compound of claim 39, wherein R.sub.1 is tetrahydronaphthyl,
decahydronaphthyl or dibenzocycloheptyl.
43. A compound of claim 39, wherein R.sub.1 is phenyl or
benzyl.
44. A compound of claim 39, wherein R.sub.1 is a bicyclic aromatic
ring.
45. A compound of claim 44, wherein said bicyclic aromatic ring is
indenyl, quinoline or naphthyl.
46. A compound of claim 39, wherein Z is a bond, methyl, or
ethyl.
47. A compound of claim 39, wherein n is 0.
48. A compound of claim 39, wherein X.sub.1 and X.sub.2 are both
O.
49. A compound selected from the group consisting of:
1,2,3,4-tetrahydro-1-[1-(naphth-2-yl-methyl)-4-piperidinyl]-quinolin-2-on-
e;
1,2,3,4-tetrahydro-1-[1-(p-phenylbenzyl)-4-piperidinyl]-quinolin-2-one;
1,2,3,4-tetrahydro-1-[1-[4,4-bis(4-fluorophenyl)butyl]-4-piperidinyl]-qui-
nolin-2-one;
1,2,3,4-tetrahydro-1-[1-(p-benzyloxybenzyl)-4-piperidinyl]-quinolin-2-one-
; 1,
2,3,4-tetrahydro-1-[1-(1,2,3,4-tetrahydro-2-naphthyl)-4-piperidinyl]--
quinolin-2-one;
1,2,3,4-tetrahydro-1-[1-(4-propyl-cyclohexyl)-4-piperidinyl]-quinolin-2-o-
ne;
1,2,3,4-tetrahydro-1-[1-(5-methylhex-2-yl)-4-piperidinyl]-quinolin-2-o-
ne;
1,2,3,4-tetrahydro-1-[1-(norbornan-2-yl)-4-piperidinyl]-quinolin-2-one-
;
1,2,3,4-tetrahydro-1-[1-(decahydro-2-naphthyl)-4-piperidinyl]-quinolin-2-
-one;
1,2,3,4-tetrahydro-1-[1-(10,11-dihydro-5H-dibenzo[a.d]-cyclohepten-5-
-yl)-4-piperidinyl]-quinolin-2-one;
1,2,3,4-tetrahydro-1-[1-(3,3-diphenylpropyl)-4-piperidinyl]-quinolin-2-on-
e;
1,2,3,4-tetrahydro-1-[1-(cyclooctyl)-4-piperidinyl]-quinolin-2-one;
1,2,3,4-tetrahydro-1-[1-[4-(1-methylethyl)-cyclohexyl]-4-piperidinyl]-qui-
nolin-2-one;
1,2,3,4-tetrahydro-1-[1-(1,3-dihydroinden-2-yl)-4-piperidinyl]-quinolin-2-
-one;
1,2,3,4-tetrahydro-1-[1-(cyclooctylmethyl)-4-piperidinyl]-quinolin-2-
-one; and pharmaceutically acceptable salts thereof.
50. A pharmaceutical composition comprising a compound of claim 33
and at least one pharmaceutically acceptable excipient.
51. A method of treating pain comprising administering to a patient
in need thereof, an effective amount of an analgesic compound
according to claim 33.
52. A method of modulating a pharmacological response from the ORL1
receptor comprising administering to a patient in need thereof, an
effective amount of a compound according to claim 33.
53. A pharmaceutical composition comprising a compound of claim 39
and at least one pharmaceutically acceptable excipient.
54. A method of treating pain comprising administering to a patient
in need thereof, an effective amount of an analgesic compound
according to claim 39.
55. A method of modulating a pharmacological response from the ORL1
receptor comprising administering to a patient in need thereof an
effective amount of a compound according to claim 39.
56. A compound of the formula (IIA): ##STR00022## wherein R.sub.2
is selected from the group consisting of hydrogen, C.sub.1-10
alkyl, C.sub.3-12 cycloalkyl and halogen, said alkyl is optionally
substituted with an oxo group; n is an integer from 0 to 3; and
ZR.sub.1 is ##STR00023## wherein Y.sub.1 is
R.sub.3--(C.sub.1-C.sub.12)alkyl, R.sub.4-aryl, R.sub.5-heteroaryl,
R.sub.6--(C.sub.3-C.sub.12)cyano-alkyl, R.sub.7--(C.sub.3-C.sub.7)
heterocycloalkyl, --CO.sub.2(C.sub.1-C.sub.6)alkyl, CN or
--C(O)NR.sub.8R.sub.9; Y.sub.2 is hydrogen or Y; Y.sub.3 is
hydrogen or (C.sub.1-C.sub.6)alkyl; or Y.sub.1, Y.sub.2 and
Y.sub.3, together with the carbon to which they are attached, form
one of the following structures: ##STR00024## wherein r is 0 to 3;
c and d are independently 1 or 2; s is 1 to 5; and ring E is a
fused R.sub.4-phenyl or R.sub.5-heteroaryl ring; R.sub.10 is 1 to 3
substituents independently selected from the-group consisting of H,
(C.sub.1-C.sub.6)alkyl, --OR.sub.9,
--(C.sub.1-C.sub.6)alkyl-OR.sub.8, --NR.sub.8R.sub.9 and
--(C.sub.1-C.sub.6)allyl-NR.sub.8R.sub.9; R.sub.11 is 1 to 3
substituents independently selected from the group consisting of
R.sub.10, --CF.sub.3, --OCF.sub.3, NO.sub.2 and halo, or R.sub.11
substituents on adjacent ring carbon atoms may together form a
methylenedioxy or ethylenedioxy ring; R.sub.8 and R.sub.9 are
independently selected from the group consisting of hydrogen,
(C.sub.1-C.sub.6) alkyl, (C.sub.3-C.sub.12) cycloalkyl, aryl and
aryl(C.sub.1-C.sub.6)alkyl; R.sub.3 is 1 to 3 substituents
independently selected from the group consisting of H,
R.sub.4-aryl, R.sub.6--(C.sub.3-C.sub.12) cycloalkyl,
R.sub.5-heteroaryl, R.sub.7--(C.sub.3-C.sub.7)heterocycloalkyl,
--NR.sub.8R.sub.9, --OR.sub.12 and --S(O).sub.0-2R.sub.12, R.sub.6
is 1 to 3 substituents independently selected from the group
consisting of H, (C.sub.1-C.sub.6)alkyl, R.sub.4-aryl,
--NR.sub.8R.sub.9, --OR.sub.12 and --SR.sub.12; R.sub.4 is 1 to 3
substituents independently selected from the group consisting of
hydrogen, halo, (C.sub.1-C.sub.6)alkyl, R.sub.13-aryl,
(C.sub.3-C.sub.12)cycloalkyl, --CN, --CF.sub.3, --OR.sub.8,
--(C.sub.1-C.sub.6)alkyl-OR.sub.8, --OCF.sub.3, NR.sub.8R.sub.9,
--(C.sub.1-C.sub.6)alkyl-NR.sub.8R.sub.9, --NHSO.sub.2R.sub.8,
--SO.sub.2N(R.sub.14).sub.2, --SO.sub.2R.sub.5, --SOR.sub.9,
--SR.sub.5, --NO.sub.2, --CONR.sub.8R.sub.9, --NR.sub.9COR.sub.8,
--COR.sub.8, --COCF.sub.3, --OCOR.sub.8, --OCO.sub.2R.sub.8,
--COOR.sub.8, --(C.sub.1-C.sub.6)allyl-NHCOOC(CH.sub.3).sub.3,
--(C.sub.1-C.sub.6)alkyl-NHCOCF.sub.3,
--(C.sub.1-C.sub.6)alkyl-NHSO.sub.2--(C.sub.1-C.sub.6) alkyl,
--(C.sub.1-C.sub.6)alkyl-NHCONH--(C.sub.1-C.sub.6)-alkyl and
##STR00025## wherein f is 0 to 6; or R.sub.4 substituents on
adjacent ring carbon atoms may together form a methylenedioxy or
ethylenedioxy ring; R.sub.5 is 1 to 3 substituents independently
selected from the group consisting of hydrogen, halo,
(C.sub.1-C.sub.6)alkyl, R.sub.13-aryl,
(C.sub.3-C.sub.12)cycloalkyl, --CN, --CF.sub.3, --OR.sub.9,
--(C.sub.1-C.sub.6)alkyl-OR.sub.8, --OCF.sub.3, --NR.sub.8R.sub.9,
--(C.sub.1-C.sub.6)alkyl-NR.sub.8R.sub.9, --NHSO.sub.2R.sub.8,
--SO.sub.2N(R.sub.14).sub.2, --NO.sub.2, --CONR.sub.8R.sub.9,
--NR.sub.9COR.sub.8, --COR.sub.8, --OCOR.sub.8, --OCO.sub.2R.sub.8
and --COOR.sub.8; R.sub.7 is H, (C.sub.1-C.sub.6)alkyl, --OR.sub.8,
--(C.sub.1-C.sub.6)alkyl-OR.sub.8, --NR.sub.8R.sub.9 or
--(C.sub.1-C.sub.6)alkyl-NR.sub.8R.sub.9; R.sub.12 is H-1,
(C.sub.1-C.sub.6)alkyl, R.sub.4-aryl,
--(C.sub.1-C.sub.6)alkyl-OR.sub.9,
--(C.sub.1-C.sub.6)alkyl-NR.sub.8R.sub.9,
--(C.sub.1-C.sub.6)alkyl-SR.sub.8, or aryl(C.sub.1-C.sub.6) alkyl;
R.sub.13 is 1-3 substituents independently selected from the group
consisting of H, (C.sub.1-C.sub.6)alkyl, (C.sub.1-C.sub.6) alkoxy
and halo; R.sub.14 is independently selected from the group
consisting of H, (C.sub.1-C.sub.6)alkyl and
R.sub.13--C.sub.6H.sub.4--CH.sub.2--; or a pharmaceutically
acceptable salt thereof.
57. A pharmaceutical composition comprising a compound of claim 56
and at least one pharmaceutically acceptable excipient.
58. A method of treating pain comprising administering to a patient
in need thereof, an effective amount of an analgesic compound
according to claim 56.
59. A method of modulating a pharmacological response from the ORL1
receptor comprising administering to a patient in need thereof, an
effective amount of a compound according to claim 56.
60. A method of modulating a pharmacological response from an
opioid receptor comprising administering to a patient in need
thereof, an effective amount of a compound according to claim
33.
61. A method of modulating a pharmacological response from an
opioid receptor comprising administering to a patient in need
thereof, an effective amount of a compound according to claim
39.
62. A method of modulating a pharmacological response from an
opioid receptor comprising administering to a patient in need
thereof, an effective amount of a compound according to claim 56.
Description
[0001] This application claims priority from U.S. Provisional
Application Ser. Nos. 60/284,674 and 60/284,676, both filed Apr.
18, 2001, the disclosures of which are hereby incorporated by
reference.
BACKGROUND OF THE INVENTION
[0002] Chronic pain is a major contributor to disability and is the
cause of an untold amount of suffering. The successful treatment of
severe and chronic pain is a primary goal of the physician with
opioid analgesics being preferred drugs.
[0003] Until recently, there was evidence of three major classes of
opioid receptors in the central nervous system (CNS), with each
class having subtype receptors. These receptor classes were
designated as .mu., .delta. and .kappa.. As opiates had a high
affinity to these receptors while not being endogenous to the body,
research followed in order to identify and isolate the endogenous
ligands to these receptors. These ligands were identified as
enkephalins, endorphins and dynorphins.
[0004] Recent experimentation has led to the identification of a
cDNA encoding an opioid receptor-like (ORL1) receptor with a high
degree of homology to the known receptor classes. This newly
discovered receptor was classified as an opioid receptor based only
on structural grounds, as the receptor did not exhibit
pharmacological homology. It was initially demonstrated that
non-selective ligands having a high affinity for .mu., .delta. and
.kappa. receptors had low affinity for the ORL1. This
characteristic, along with the fact that an endogenous ligand had
not yet been discovered, led to the term "orphan receptor".
[0005] Subsequent research led to the isolation and structure of
the endogenous ligand of the ORL1 receptor. This ligand is a
seventeen amino acid peptide structurally similar to members of the
opioid peptide family.
[0006] The discovery of the ORL1 receptor presents an opportunity
in drug discovery for novel compounds which can be administered for
pain management or other syndromes modulated by this receptor.
[0007] All documents cited herein, including the foregoing, are
incorporated by reference in their entireties for all purposes.
OBJECTS AND SUMMARY OF THE INVENTION
[0008] It is accordingly an object of certain embodiments of the
present invention to provide new compounds which exhibit affinity
for the ORL1 receptor.
[0009] It is an object of certain embodiments of the present
invention to provide new compounds which exhibit affinity for the
ORL1 receptor and one or more of the .mu., .delta. or .kappa.
receptors.
[0010] It is an object of certain embodiments of the present
invention to provide new compounds for treating a patient suffering
from chronic or acute pain by administering a compound having
affinity for the ORL1 receptor.
[0011] It is an object of certain embodiments of the present
invention to provide new compounds which have agonist activity at
the .mu., .delta. and .kappa. receptors which is greater than
compounds currently available e.g. morphine.
[0012] It is an object of certain embodiments of the present
invention to provide methods of treating chronic and acute pain by
administering compounds which have agonist activity at the .mu.,
.delta. and .kappa. receptors which is greater than compounds
currently available.
[0013] It is an object of certain embodiments of the present
invention to provide methods of treating chronic and acute pain by
administering non-opioid compounds which have agonist activity at
the .mu., .delta. and .kappa. receptors and which produce less side
effects than compounds currently available.
[0014] It is an object of certain embodiments of the present
invention to provide compounds useful as analgesics,
anti-inflammatories, diuretics, anesthetics and neuroprotective
agents, anti-hypertensives, anti-anxiolytics; agents for appetite
control; hearing regulators; anti-tussives, anti-asthmatics,
modulators of locomotor activity, modulators of learning and
memory, regulators of neurotransmitter and hormone release, kidney
function modulators, anti-depressants, agents to treat memory loss
due to Alzheimer's disease or other dementias, anti-epileptics,
anti-convulsants, agents to treat withdrawal from alcohol and drugs
of addiction, agents to control water balance, agents to control
sodium excretion and agents to control arterial blood pressure
disorders and methods for administering said compounds.
[0015] The compounds of the present invention are useful for
modulating a pharmacodynamic response from one or more opioid
receptors (ORL-1, .mu., .delta. and .kappa.) centrally and/or
peripherally. The response can be attributed to the compound
stimulating (agonist) or inhibiting (antagonist) the one or more
receptors. Certain compounds can stimulate one receptor (e.g., a 1
agonist) and inhibit a different receptor (e.g., an ORL-1
antagonist).
[0016] Other objects and advantages of the present invention will
become apparent from the following detailed description thereof.
The present invention in certain embodiments comprises compounds
having the general formula (I):
##STR00002##
[0017] wherein W is hydrogen, C.sub.1-10 alkyl, C.sub.3-12
cycloalkyl, C.sub.3-12 cycloalkylC.sub.1-4alkyl-, C.sub.1-10
alkoxy, C.sub.3-12 cycloalkoxy-, C.sub.1-10 alkyl substituted with
1-3 halogen, C.sub.3-12 cycloalkyl substituted with 1-3 halogen,
C.sub.3-12 cycloalkylC.sub.1-4alkyl-substituted with 1-3 halogen,
C.sub.1-10 alkoxy substituted with 1-3 halogen, C.sub.3-12
cycloalkoxy-substituted with 1-3 halogen, --COOV.sub.1,
--C.sub.1-4COOV.sub.1, --CH.sub.2OH, --SO.sub.2N(V.sub.1).sub.2,
hydroxyC.sub.3-10alkyl-, hydroxyC.sub.3-10cycloalkyl-,
cyanoC.sub.1-10alkyl-, cyanoC.sub.3-10cycloalkyl-,
--CON(V.sub.1).sub.2, NH.sub.2SO.sub.2C.sub.1-4alkyl-,
NH.sub.2SOC.sub.1-4alkyl-, sulfonylaminoC.sub.1-10alkyl-,
diaminoalkyl-, -sulfonylC.sub.1-4alkyl, a 6-membered heterocyclic
ring, a 6-membered heteroaromatic ring, a 6-membered
heterocyclicC.sub.1-4alkyl-, a 6-membered
heteroaromaticC.sub.1-4alkyl-, a 6-membered aromatic ring, a
6-membered aromaticC.sub.1-4 alkyl-, a 5-membered heterocyclic ring
optionally substituted with an oxo or thio, a 5-membered
heteroaromatic ring, a 5-membered
heterocyclicC.sub.1-4alkyl-optionally substituted with an oxo or
thio, a 5-membered heteroaromaticC.sub.1-4alkyl-,
--C.sub.1-5(.dbd.O)W.sub.1, --C.sub.1-5(.dbd.NH)W.sub.1,
--C.sub.1-5NHC(.dbd.O)W.sub.1, --C.sub.1-5NHS(.dbd.O).sub.2W.sub.1,
--C.sub.1-5NHS(.dbd.O)W.sub.1, wherein W.sub.1 is hydrogen,
C.sub.1-10 alkyl, C.sub.3-12 cycloalkyl, C.sub.1-10 alkoxy,
C.sub.3-12 cycloalkoxy, --CH.sub.2OH, amino, C.sub.1-4alkylamino-,
diC.sub.1-4alkylamino-, or a 5-membered heteroaromatic ring
optionally substituted with 1-3 lower alkyl;
[0018] wherein each V.sub.1 is independently selected from H,
C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, benzyl and phenyl;
[0019] Q is a 5-8 membered cycloalkyl, 5-8 membered heterocyclic or
a 6 membered aromatic or heteroaromatic group;
[0020] each n is independently an integer from 0 to 3;
[0021] A, B and C are independently hydrogen, C.sub.1-10 alkyl,
C.sub.3-12 cycloalkyl, C.sub.1-10 alkoxy, C.sub.3-12 cycloalkoxy,
--CH.sub.2OH, --NHSO.sub.2, hydroxyC.sub.1-10alkyl-,
aminocarbonyl-, C.sub.1-4alkylaminocarbonyl-,
diC.sub.1-4alkylaminocarbonyl-, acylamino-, acylaminoalkyl-, amide,
sulfonylaminoC.sub.1-10alkyl-, or A-B can together form a C.sub.2-6
bridge, or B-C can together form a C.sub.3-7 bridge, or A-C can
together form a C.sub.1-5 bridge;
[0022] Z is selected from the group consisting of a bond, straight
or branched C.sub.1-6 alkylene, --NH--, --CH.sub.2O--,
--CH.sub.2NH--, --CH.sub.2N(CH.sub.3)--, --NHCH.sub.2--,
--CH.sub.2CONH--, --NHCH.sub.2CO--, --CH.sub.2CO--, --COCH.sub.2--,
--CH.sub.2COCH.sub.2--, --CH(CH.sub.3)--, --CH.dbd., --O-- and
--HC.dbd.CH--, wherein the carbon and/or nitrogen atoms are
unsubstituted or substituted with one or more lower alkyl, hydroxy,
halo or alkoxy group;
[0023] R.sub.1 is selected from the group consisting of hydrogen,
C.sub.1-10 alkyl, C.sub.3-12cycloalkyl, C.sub.2-10alkenyl, amino,
C.sub.1-10alkylamino-, C.sub.3-12cycloalkylamino-, --COOV.sub.1,
--C.sub.1-4COOV.sub.1, cyano, cyanoC.sub.1-10alkyl-,
cyanoC.sub.3-10cycloalkyl-, NH.sub.2SO.sub.2--,
NH.sub.2SO.sub.2C.sub.1-4alkyl-, NH.sub.2SOC.sub.1-4alkyl-,
aminocarbonyl-, C.sub.1-4alkylaminocarbonyl-,
diC.sub.1-4alkylaminocarbonyl-, benzyl, C.sub.3-12cycloalkenyl-, a
monocyclic, bicyclic or tricyclic aryl or heteroaryl ring, a
hetero-monocyclic ring, a hetero-bicyclic ring system, and a spiro
ring system of the formula (III):
##STR00003##
[0024] wherein X.sub.1 and X.sub.2 are independently selected from
the group consisting of NH, O, S and CH.sub.2; and wherein said
alkyl, cycloalkyl, alkenyl, C.sub.1-10alkylamino-,
C.sub.3-12cycloalkylamino-, or benzyl of R.sub.1 is optionally
substituted with 1-3 substituents selected from the group
consisting of halogen, hydroxy, C.sub.1-10 alkyl, C.sub.1-10
alkoxy, nitro, trifluoromethyl-, cyano, --COOV.sub.1,
--C.sub.1-4COOV.sub.1, cyanoC.sub.1-10alkyl-,
--C.sub.1-5(.dbd.O)W.sub.1, --C.sub.1-5NHS(.dbd.O).sub.2W.sub.1,
--C.sub.1-5NHS(.dbd.O)W.sub.1, a 5-membered
heteroaromaticC.sub.0-4alkyl-, phenyl, benzyl, benzyloxy, said
phenyl, benzyl, and benzyloxy optionally being substituted with 1-3
substituents selected from the group consisting of halogen,
C.sub.1-10 alkyl-, C.sub.1-10 alkoxy-, and cyano; and wherein said
C.sub.3-12 cycloalkyl, C.sub.3-12 cycloalkenyl, monocyclic,
bicyclic or tricyclic aryl, heteroaryl ring, hetero-monocyclic
ring, hetero-bicyclic ring system, or spiro ring system of the
formula (III) is optionally substituted with 1-3 substituents
selected from the group consisting of halogen, C.sub.1-10 alkyl,
C.sub.1-10 alkoxy, nitro, trifluoromethyl-, phenyl, benzyl,
phenyloxy and benzyloxy, wherein said phenyl, benzyl, phenyloxy or
benzyloxy is optionally substituted with 1-3 substituents selected
from the group consisting of halogen, C.sub.1-10 alkyl, C.sub.1-10
alkoxy, and cyano;
[0025] R.sub.2 is selected from the group consisting of hydrogen,
C.sub.1-10 alkyl, C.sub.3-12 cycloalkyl- and halogen, said alkyl or
cycloalkyl optionally substituted with an oxo, amino, alkylamino or
dialkylamino group;
[0026] and pharmaceutically acceptable salts thereof and solvates
thereof.
[0027] The present invention in certain embodiments comprises
compounds having the formula (IA):
##STR00004##
[0028] wherein
[0029] each n is independently an integer from 0 to 3;
[0030] Z is selected from the group consisting of a bond,
--CH.sub.2--, --NH--, --CH.sub.2O--, --CH.sub.2CH.sub.2--,
--CH.sub.2NH--, --CH.sub.2N(CH.sub.3)--, --NHCH.sub.2--,
--CH.sub.2CONH--, --NHCH.sub.2CO--, --CH.sub.2CO--, --COCH.sub.2--,
--CH.sub.2COCH.sub.2--, --CH(CH.sub.3)--, --CH.dbd., and
--HC.dbd.CH--, wherein the carbon and/or nitrogen atoms are
unsubstituted or substituted with a lower alkyl, halogen, hydroxy
or alkoxy group;
[0031] R.sub.1 is selected from the group consisting of hydrogen,
C.sub.1-10alkyl, C.sub.3-12cycloalkyl, C.sub.2-10alkenyl, amino,
C.sub.1-10allylamino, C.sub.3-12cycloalkylamino, benzyl, C.sub.3-12
cycloalkenyl, a monocyclic, bicyclic or tricyclic aryl or
heteroaryl ring, a hetero-monocyclic ring, a hetero-bicyclic ring
system, and a spiro ring system of the formula (III):
##STR00005##
[0032] wherein X.sub.1 and X.sub.2 are independently selected from
the group consisting of NH, O, S and CH.sub.2;
[0033] wherein said monocyclic aryl is preferably phenyl;
[0034] wherein said bicyclic aryl is preferably naphthyl;
[0035] wherein said alkyl, cycloalkyl, alkenyl,
C.sub.1-10alkylamino, C.sub.3-12cycloalkylamino, or benzyl is
optionally substituted with 1-3 substituents selected from the
group consisting of halogen, C.sub.1-10 alkyl, C.sub.1-10 alkoxy,
nitro, trifluoromethyl, cyano, phenyl, benzyl, benzyloxy, said
phenyl, benzyl, and benzyloxy optionally being substituted with 1-3
substituents selected from the group consisting of halogen,
C.sub.1-10 alkyl, C.sub.1-10 alkoxy, and cyano;
[0036] wherein said C.sub.3-12 cycloalkyl, C.sub.3-12 cycloalkenyl,
monocyclic, bicyclic or tricyclic aryl, heteroaryl ring,
hetero-monocyclic ring, hetero-bicyclic ring system, and spiro ring
system of the formula (III) are optionally substituted with 1-3
substituents selected from the group consisting of halogen,
C.sub.1-10 alkyl, C.sub.1-10 alkoxy, nitro, trifluoromethyl,
phenyl, benzyl, phenyloxy and benzyloxy, wherein said phenyl,
benzyl, phenyloxy and benzyloxy are optionally substituted with 1-3
substituents selected from the group consisting of halogen,
C.sub.1-10 alkyl, C.sub.1-10 alkoxy, and cyano;
[0037] R.sub.2 is selected from the group consisting of hydrogen,
C.sub.1-10 alkyl, C.sub.3-12 cycloalkyl and halogen, said alkyl
optionally substituted with an oxo group;
[0038] and pharmaceutically acceptable salts thereof and solvates
thereof.
[0039] The present invention in certain embodiments comprises
compounds having the general formula (II):
##STR00006##
[0040] wherein W is hydrogen, C.sub.1-10 alkyl, C.sub.3-12
cycloalkyl, C.sub.3-12 cycloalkylC.sub.1-4alkyl-, C.sub.1-10
alkoxy, C.sub.3-12 cycloalkoxy-, C.sub.1-10 alkyl substituted with
1-3 halogen, C.sub.3-12 cycloalkyl substituted with 1-3 halogen,
C.sub.3-12 cycloalkylC.sub.1-4alkyl-substituted with 1-3 halogen,
C.sub.1-10alkoxy substituted with 1-3 halogen, C.sub.3-12
cycloalkoxy-substituted with 1-3 halogen, --COOV.sub.1,
--C.sub.1-4COOV.sub.1, --CH.sub.2OH, --SO.sub.2N(V.sub.1).sub.2,
hydroxyC.sub.1-10alkyl-, hydroxyC.sub.3-10cycloalkyl-,
cyanoC.sub.1-10alkyl-, cyanoC.sub.3-10cycloalkyl-,
--CON(V.sub.1).sub.2, NH.sub.2SO.sub.2C.sub.1-4alkyl-,
NH.sub.2SOC.sub.1-4alkyl-, sulfonylaminoC.sub.1-10alkyl-,
diaminoalkyl-, -sulfonylC.sub.1-4alkyl, a 6-membered heterocyclic
ring, a 6-membered heteroaromatic ring, a 6-membered
heterocyclicC.sub.1-4alkyl-, a 6-membered
heteroaromaticC.sub.1-4alkyl-, a 6-membered aromatic ring, a
6-membered aromaticC.sub.1-4 alkyl-, a 5-membered heterocyclic ring
optionally substituted with an oxo or thio, a 5-membered
heteroaromatic ring, a 5-membered heterocyclicC.sub.1-4alkyl-
optionally substituted with an oxo or thio, a 5-membered
heteroaromaticC.sub.1-4alkyl-, --C.sub.1-5(.dbd.O)W.sub.1,
--C.sub.1-5(.dbd.NH)W.sub.1, --C.sub.1-5NHC(.dbd.O)W.sub.1,
--C.sub.1-5NHS(.dbd.O).sub.2W.sub.1, --C.sub.1-5NHS(.dbd.O)W.sub.1,
wherein W.sub.1 is hydrogen, C.sub.1-10 alkyl, C.sub.3-12
cycloalkyl, C.sub.1-10 alkoxy, C.sub.3-12 cycloalkoxy,
--CH.sub.2OH, amino, C.sub.1-4alkylamino-, diC.sub.1-4alkylamino-,
or a 5-membered heteroaromatic ring optionally substituted with 1-3
lower alkyl;
[0041] wherein each V.sub.1 is independently selected from H,
C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, benzyl and phenyl;
[0042] Q is a 5-8 membered cycloalkyl, 5-8 membered heterocyclic or
a 6 membered aromatic or heteroaromatic group;
[0043] n is an integer from 0 to 3;
[0044] A, B and C are independently hydrogen, C.sub.1-10 allyl,
C.sub.3-12 cycloalkyl, C.sub.1-10 alkoxy, C.sub.3-12 cycloalkoxy,
--CH.sub.2OH, --NHSO.sub.2, hydroxyC.sub.1-10alkyl-,
aminocarbonyl-, C.sub.1-4alkylaminocarbonyl-,
diC.sub.1-4alkylaminocarbonyl-, acylamino-, acylaminoalkyl-, amide,
sulfonylaminoC.sub.1-10alkyl-, or A-B can together form a C.sub.2-6
bridge, or B-C can together form a C.sub.3-7 bridge, or A-C can
together form a C.sub.1-5 bridge;
[0045] Z is selected from the group consisting of a bond, straight
or branched C.sub.1-6 alkylene, --NH--, --CH.sub.2O--,
--CH.sub.2NH--, --CH.sub.2N(CH.sub.3)--, --NHCH.sub.2--,
--CH.sub.2CONH--, --NHCH.sub.2CO--, --CH.sub.2CO--, --COCH.sub.2--,
--CH.sub.2COCH.sub.2--, --CH(CH.sub.3)--, --CH.dbd., --O-- and
--HC.dbd.CH--, wherein the carbon and/or nitrogen atoms are
unsubstituted or substituted with one or more lower alkyl, hydroxy,
halo or alkoxy group;
[0046] R.sub.1 is selected from the group consisting of hydrogen,
C.sub.1-10 alkyl, C.sub.3-12cycloalkyl, C.sub.2-10alkenyl, amino,
C.sub.1-10alkylamino-, C.sub.3-12cycloalkylamino-, --COOV.sub.1,
--C.sub.1-4COOV.sub.1, cyano, cyanoC.sub.1-10alkyl-,
cyanoC.sub.3-10cycloalkyl-, NH.sub.2SO.sub.2--,
NH.sub.2SO.sub.2C.sub.1-4allyl-, NH.sub.2SOC.sub.1-4alkyl-,
aminocarbonyl-, C.sub.1-4alkylaminocarbonyl-,
diC.sub.1-4alkylaminocarbonyl-, benzyl, C.sub.3-12 cycloalkenyl-, a
monocyclic, bicyclic or tricyclic aryl or heteroaryl ring, a
hetero-monocyclic ring, a hetero-bicyclic ring system, and a spiro
ring system of the formula (III):
##STR00007##
[0047] wherein X.sub.1 and X.sub.2 are independently selected from
the group consisting of NH, O, S and CH.sub.2; and wherein said
alkyl, cycloalkyl, alkenyl, C.sub.1-10alkylamino-,
C.sub.3-12cycloalkylamino-, or benzyl of R.sub.1 is optionally
substituted with 1-3 substituents selected from the group
consisting of halogen, hydroxy, C.sub.1-10 alkyl, C.sub.1-10
alkoxy, nitro, trifluoromethyl-, cyano, --COOV.sub.1,
--C.sub.1-4COOV.sub.1, cyanoC.sub.1-10alkyl-,
--C.sub.1-5(.dbd.O)W.sub.1, --C.sub.1-5NHS(.dbd.O).sub.2W.sub.1,
--C.sub.1-5NHS(.dbd.O)W.sub.1, a 5-membered
heteroaromaticC.sub.0-4alkyl-, phenyl, benzyl, benzyloxy, said
phenyl, benzyl, and benzyloxy optionally being substituted with 1-3
substituents selected from the group consisting of halogen,
C.sub.1-10 alkyl-, C.sub.1-10 alkoxy-, and cyano; and wherein said
C.sub.3-12 cycloalkyl, C.sub.3-12 cycloalkenyl, monocyclic,
bicyclic or tricyclic aryl, heteroaryl ring, hetero-monocyclic
ring, hetero-bicyclic ring system, or spiro ring system of the
formula (III) is optionally substituted with 1-3 substituents
selected from the group consisting of halogen, C.sub.1-10 alkyl,
C.sub.1-10 alkoxy, nitro, trifluoromethyl-, phenyl, benzyl,
phenyloxy and benzyloxy, wherein said phenyl, benzyl, phenyloxy or
benzyloxy is optionally substituted with 1-3 substituents selected
from the group consisting of halogen, C.sub.1-10 alkyl, C.sub.1-10
alkoxy, and cyano;
[0048] R.sub.2 is selected from the group consisting of hydrogen,
C.sub.1-10 alkyl, C.sub.3-12 cycloalkyl- and halogen, said alkyl or
cycloalkyl optionally substituted with an oxo, amino, alkylamino or
dialkylamino group;
[0049] and pharmaceutically acceptable salts thereof and solvates
thereof.
[0050] The present invention in certain embodiments comprises
compounds having the formula (IIA) as follows:
##STR00008##
[0051] wherein
[0052] n is an integer from 0 to 3;
[0053] Z is selected from the group consisting of a bond,
--CH.sub.2--, --NH--, --CH.sub.2O--, --CH.sub.2CH.sub.2--,
--CH.sub.2NH--, --CH.sub.2N(CH.sub.3)--, --NHCH.sub.2--,
--CH.sub.2CONH--, --NHCH.sub.2CO--, --CH.sub.2CO--, --COCH.sub.2--,
--CH.sub.2COCH.sub.2--, --CH(CH.sub.3)--, --CH.dbd., and
--HC.dbd.CH--, wherein the carbon and/or nitrogen atoms are
unsubstituted or substituted with a lower alkyl, halogen, hydroxy
or alkoxy group;
[0054] R.sub.1 is selected from the group consisting of hydrogen,
C.sub.1-10alkyl, C.sub.3-12cycloalkyl, C.sub.2-10alkenyl, amino,
C.sub.1-10alkylamino, C.sub.3-12cycloalkylamino, benzyl, C.sub.3-12
cycloalkenyl, a monocyclic, bicyclic or tricyclic aryl or
heteroaryl ring, a hetero-monocyclic ring, a hetero-bicyclic ring
system, and a spiro ring system of the formula (III):
##STR00009##
[0055] wherein X.sub.1 and X.sub.2 are independently selected from
the group consisting of NH, O, S and CH.sub.2;
[0056] wherein said monocyclic aryl is preferably phenyl;
[0057] wherein said bicyclic aryl is preferably naphthyl;
[0058] wherein said alkyl, cycloalkyl, alkenyl,
C.sub.1-10alkylamino, C.sub.3-12cycloalkylamino, or benzyl is
optionally substituted with 1-3 substituents selected from the
group consisting of halogen, C.sub.1-10 alkyl, C.sub.1-10 alkoxy,
nitro, trifluoromethyl, cyano, phenyl, benzyl, benzyloxy, said
phenyl, benzyl, and benzyloxy optionally being substituted with 1-3
substituents selected from the group consisting of halogen,
C.sub.1-10 alkyl, C.sub.1-10 alkoxy, and cyano;
[0059] wherein said C.sub.3-12 cycloalkyl, C.sub.3-12 cycloalkenyl,
monocyclic, bicyclic or tricyclic aryl, heteroaryl ring,
hetero-monocyclic ring, hetero-bicyclic ring system, and spiro ring
system of the formula (III) are optionally substituted with 1-3
substituents selected from the group consisting of halogen,
C.sub.1-10 alkyl, C.sub.1-10 alkoxy, nitro, trifluoromethyl,
phenyl, benzyl, phenyloxy and benzyloxy, wherein said phenyl,
benzyl, phenyloxy and benzyloxy are optionally substituted with 1-3
substituents selected from the group consisting of halogen,
C.sub.1-10 alkyl, C.sub.1-10 alkoxy, and cyano;
[0060] R.sub.2 is selected from the group consisting of hydrogen,
C.sub.1-10 alkyl, C.sub.3-12 cycloalkyl and halogen, said alkyl
optionally substituted with an oxo group;
[0061] and pharmaceutically acceptable salts thereof and solvates
thereof.
[0062] In certain preferred embodiments of formula (I) or (II), Q
is phenyl or a 6 membered heteroaromatic group containing 1-3
nitrogen atoms.
[0063] In certain preferred embodiments of formula (I), (II), (IA)
or (IIA), the R.sub.1 alkyl is methyl, ethyl, propyl, butyl,
pentyl, or hexyl.
[0064] In certain preferred embodiments of formula (I), (II), (IA)
or (IIA), the R.sub.1 cycloalkyl is cyclohexyl, cycloheptyl,
cyclooctyl, cyclononyl, cyclodecyl, or norbornyl.
[0065] In other preferred embodiments of formula (I), (II), (IA) or
(IIA), the R.sub.1 bicyclic ring system is naphthyl. In other
preferred embodiments of formula (I), (II), (IA) or (IIA), the
R.sub.1 bicyclic ring system is tetrahydronaphthyl, or
decahydronaphthyl and the R.sub.1 tricyclic ring system is
dibenzocycloheptyl. In other preferred embodiments R.sub.1 is
phenyl or benzyl.
[0066] In other preferred embodiments of formula (J), (II), (IA) or
(IIA), the R.sub.1 bicyclic aromatic ring is a 10-membered ring,
preferably quinoline or naphthyl.
[0067] In other preferred embodiments of formula (I), (II), (IA) or
(IIA), the R.sub.1 bicyclic aromatic ring is a 9-membered ring,
preferably indenyl.
[0068] In certain embodiments of formula (I), (II), (IA) or (IIA),
Z is a bond, methyl, or ethyl.
[0069] In certain embodiments of formula (I), (II), (IA) or (IIA),
the Z group is maximally substituted as not to have any hydrogen
substitution on the base Z group. For example, if the base Z group
is --CH.sub.2--, substitution with two methyl groups would remove
hydrogens from the --CH.sub.2-- base Z group.
[0070] In other preferred embodiments of formula (I), (II), (IA) or
(IIA), n is 0.
[0071] In certain embodiments of formula (I), (II), (IA) or (IIA),
X.sub.1 and X.sub.2 are both O.
[0072] In certain embodiments of formula (J) or (II), W is
--CH.sub.2C(.dbd.O)NH.sub.2, --C(NH)NH.sub.2, pyridylmethyl,
cyclopentyl, cyclohexyl, furanylmethyl, --C(.dbd.O)CH.sub.3,
--CH.sub.2CH.sub.2NHC(.dbd.O)CH.sub.3, --SO.sub.2CH.sub.3,
CH.sub.2CH.sub.2NHSO.sub.2CH.sub.3, furanylcarbonyl-,
methylpyrrolylcarbonyl-, diazolecarbonyl-, azolemethyl-,
trifluoroethyl-, hydroxyethyl-, cyanomethyl-, oxo-oxazolemethyl-,
or diazolemethyl-.
[0073] In certain embodiments of formula (I) or (II), ZR.sub.1 is
cyclohexylethyl-, cyclohexylmethyl-, cyclopentylmethyl-,
dimethylcyclohexylmethyl-, phenylethyl-, pyrrolyltrifluoroethyl-,
thienyltrifluoroethyl-, pyridylethyl-, cyclopentyl-, cyclohexyl-,
methoxycyclohexyl-, tetrahydropyranyl-, propylpiperidinyl-,
indolylmethyl-, pyrazoylpentyl-, thiazolylethyl-,
phenyltrifluoroethyl-, hydroxyhexyl-, methoxyhexyl-,
isopropoxybutyl-, hexyl-, or oxocanylpropyl-.
[0074] In certain embodiments of formula (J) or (II), at least one
of ZR.sub.1 or W is --CH.sub.2COOV.sub.1, tetrazolylmethyl-,
cyanomethyl-, NH.sub.2SO.sub.2methyl-, NH.sub.2SOmethyl-,
aminocarbonylmethyl-, C.sub.1-4alkylaminocarbonylmethyl-, or
diC.sub.1-4alkylaminocarbonylmethyl-.
[0075] In certain embodiments of formula (I) or (II), ZR.sub.1 is
3,3 diphenylpropyl optionally substituted at the 3 carbon of the
propyl with --COOV.sub.1, tetrazolylC.sub.1-4alkyl-, cyano-,
aminocarbonyl-, C.sub.1-4alkylaminocarbonyl-, or
diC.sub.1-4alkylaminocarbonyl-.
[0076] In alternate embodiments ZR.sub.1 in formula (I), (II), (IA)
or (IIA) can be
##STR00010##
[0077] wherein
[0078] Y.sub.1 is R.sub.3--(C.sub.1-C.sub.12)alkyl, R.sub.4-aryl,
R.sub.5-heteroaryl, R.sub.6--(C.sub.3-C.sub.12)cyclo-alkyl,
R.sub.7--(C.sub.3-C.sub.7)heterocycloalkyl,
--CO.sub.2(C.sub.1-C.sub.6)alkyl, CN or --C(O)NR.sub.8R.sub.9;
Y.sub.2 is hydrogen or Y; Y.sub.3 is hydrogen or
(C.sub.1-C.sub.6)alkyl; or Y.sub.1, Y.sub.2 and Y.sub.3, together
with the carbon to which they are attached, form one of the
following structures:
##STR00011##
[0079] wherein r is 0 to 3; w and u are each 0-3, provided that the
sum of w and u is 1-3; c and d are independently 1 or 2; s is 1 to
5; and ring E is a fused R.sub.4-phenyl or R.sub.5-heteroaryl
ring;
[0080] R.sub.10 is 1 to 3 substituents independently selected from
the group consisting of H, (C.sub.1-C.sub.6)alkyl, --OR.sub.8,
--(C.sub.1-C.sub.6)alkyl-OR.sub.8, --NR.sub.8R.sub.9 and
--(C.sub.1-C.sub.6)alkyl-NR.sub.8R.sub.9;
[0081] R.sub.11 is 1 to 3 substituents independently selected from
the group consisting of R.sub.10, --CF.sub.3, --OCF.sub.3, NO.sub.2
and halo, or R.sub.11 substituents on adjacent ring carbon atoms
may together form a methylenedioxy or ethylenedioxy ring;
[0082] R.sub.8 and R.sub.9 are independently selected from the
group consisting of hydrogen, (C.sub.1-C.sub.6) alkyl,
(C.sub.3-C.sub.12)cycloalkyl, aryl and
aryl(C.sub.1-C.sub.6)alkyl;
[0083] R.sub.3 is 1 to 3 substituents independently selected from
the group consisting of H, R.sub.4-aryl,
R.sub.6--(C.sub.3-C.sub.12)cycloalkyl, R.sub.5-heteroaryl,
R.sub.7--(C.sub.3-C.sub.7)heterocycloalkyl, --NR.sub.8R.sub.9,
--OR.sub.12 and --S(O).sub.0-2R.sub.12;
[0084] R.sub.6 is 1 to 3 substituents independently selected from
the group consisting of H, (C.sub.1-C.sub.6)alkyl, R.sub.4-aryl,
--NR.sub.8R.sub.9, --OR.sub.12 and --SR.sub.12;
[0085] R.sub.4 is 1 to 3 substituents independently selected from
the group consisting of hydrogen, halo, (C.sub.1-C.sub.6)alkyl,
R.sub.13-aryl, (C.sub.3-C.sub.12)cycloalkyl, --CN, --CF.sub.3,
--OR.sub.8, --(C.sub.1-C.sub.6)alkyl-OR.sub.8, --OCF.sub.3,
--NR.sub.8R.sub.9, --(C.sub.1-C.sub.6)alkyl --NR.sub.8R.sub.9,
--NHSO.sub.2R.sub.8, --SO.sub.2N(R.sub.14).sub.2,
--SO.sub.2R.sub.8, --SOR.sub.8, --SR.sub.8, --NO.sub.2,
--CONR.sub.8R.sub.9, --NR.sub.9COR.sub.8, --COR.sub.8,
--COCF.sub.3, --OCOR.sub.8, --OCO.sub.2R.sub.8, --COOR.sub.8,
--(C.sub.1-C.sub.6)alkyl-NHCOOC(CH.sub.3).sub.3,
--(C.sub.1-C.sub.6)alkyl-NHCOCF.sub.3,
--(C.sub.1-C.sub.6)alkyl-NHSO.sub.2--(C.sub.1-C.sub.6)alkyl,
--(C.sub.1-C.sub.6)alkyl-NHCONH--(C.sub.1-C.sub.6)-alkyl and
##STR00012##
[0086] wherein f is 0 to 6; or R.sub.4 substituents on adjacent
ring carbon atoms may together form a methylenedioxy or
ethylenedioxy ring;
[0087] R.sub.5 is 1 to 3 substituents independently selected from
the group consisting of hydrogen, halo, (C.sub.1-C.sub.6)alkyl,
R.sub.13-aryl, (C.sub.3-C.sub.12)cycloalkyl, --CN, --CF.sub.3,
--OR.sub.8, --(C.sub.1-C.sub.6)alkyl-OR.sub.8, --OCF.sub.3,
--NR.sub.8R.sub.9, --(C.sub.1-C.sub.6)alkyl-NR.sub.8R.sub.9,
--NHSO.sub.2R.sub.8, --SO.sub.2N(R.sub.14).sub.2, --NO.sub.2,
--CONR.sub.8R.sub.9, --NR.sub.9COR.sub.8, --COR.sub.8,
--OCOR.sub.8, --OCO.sub.2R.sub.8 and --COOR.sub.8;
[0088] R.sub.7 is H, (C.sub.1-C.sub.6)alkyl, --OR.sub.8,
--(C.sub.1-C.sub.6)alkyl-OR.sub.8, --NR.sub.8R.sub.9 or
--(C.sub.1-C.sub.6)alkyl-NR.sub.8R.sub.9;
[0089] R.sub.12 is H, (C.sub.1-C.sub.6)alkyl, R.sub.4-aryl,
--(C.sub.1-C.sub.6)alkyl-OR.sub.8,
--(C.sub.1-C.sub.6)alkyl-NR.sub.8R.sub.9,
--(C.sub.1-C.sub.6)alkyl-SR.sub.8, or
aryl(C.sub.1-C.sub.6)alkyl;
[0090] R.sub.13 is 1-3 substituents independently selected from the
group consisting of H, (C.sub.1-C.sub.6)alkyl,
(C.sub.1-C.sub.6)alkoxy and halo;
[0091] R.sub.14 is independently selected from the group consisting
of H, (C.sub.1-C.sub.6)alkyl and
R.sub.13--C.sub.6H.sub.4--CH.sub.2--.
[0092] As used herein, the term "alkyl" means a linear or branched
saturated aliphatic hydrocarbon group having a single radical and
1-10 carbon atoms. Examples of alkyl groups include methyl, propyl,
isopropyl, butyl, n-butyl, isobutyl, sec-butyl, tert-butyl, and
pentyl. A branched alkyl means that one or more alkyl groups such
as methyl, ethyl or propyl, replace one or both hydrogens in a
--CH.sub.2-- group of a linear alkyl chain. The term "lower alkyl"
means an alkyl of 1-3 carbon atoms.
[0093] The term "alkoxy" means an "alkyl" as defined above
connected to an oxygen radical.
[0094] The term "cycloalkyl" means a non-aromatic mono- or
multicyclic hydrocarbon ring system having a single radical and
3-12 carbon atoms. Exemplary monocyclic cycloalkyl rings include
cyclopropyl, cyclopentyl, and cyclohexyl. Exemplary multicyclic
cycloalkyl rings include adamantyl and norbornyl.
[0095] The term "alkenyl" means a linear or branched aliphatic
hydrocarbon group containing a carbon-carbon double bond having a
single radical and 2-10 carbon atoms.
[0096] A "branched" alkenyl means that one or more alkyl groups
such as methyl, ethyl or propyl replace one or both hydrogens in a
--CH.sub.2-- or --CH=linear alkenyl chain. Exemplary alkenyl groups
include ethenyl, 1- and 2-propenyl, 1-, 2- and 3-butenyl,
3-methylbut-2-enyl, 2-propenyl, heptenyl, octenyl and decenyl.
[0097] The term "cycloalkenyl" means a non-aromatic monocyclic or
multicyclic hydrocarbon ring system containing a carbon-carbon
double bond having a single radical and 3 to 12 carbon atoms.
Exemplary monocyclic cycloalkenyl rings include cyclopropenyl,
cyclopentenyl, cyclohexenyl or cycloheptenyl. An exemplary
multicyclic cycloalkenyl ring is norbornenyl.
[0098] The term "aryl" means a carbocyclic aromatic ring system
containing one, two or three rings which may be attached together
in a pendent manner or fused, and containing a single radical.
Exemplary aryl groups include phenyl, naphthyl and acenaphthyl.
[0099] The term "heterocyclic" means cyclic compounds having one or
more heteroatoms (atoms other than carbon) in the ring, and having
a single radical. The ring may be saturated, partially saturated or
unsaturated, and the heteroatoms may be selected from the group
consisting of nitrogen, sulfur and oxygen. Examples of saturated
heterocyclic radicals include saturated 3 to 6-membered
hetero-monocyclic groups containing 1 to 4 nitrogen atoms, such as
pyrrolidinyl, imidazolidinyl, piperidino, piperazinyl; saturated 3-
to 6-membered hetero-monocyclic groups containing 1 to 2 oxygen
atoms and 1 to 3 nitrogen atoms, such as morpholinyl; saturated 3-
to 6-membered hetero-monocyclic groups containing 1 to 2 sulfur
atoms and 1 to 3 nitrogen atoms, such as thiazolidinyl. Examples of
partially saturated heterocyclic radicals include dihydrothiophene,
dihydropyran, and dihydrofuran. Other heterocyclic groups can be 7
to 10 carbon rings substituted with heteroatoms such as oxocanyl
and thiocanyl. When the heteroatom is sulfur, the sulfur can be a
sulfur dioxide such as thiocanyldioxide.
[0100] The term "heteroaryl" means unsaturated heterocyclic
radicals, wherein "heterocyclic" is as previously described.
Exemplary heteroaryl groups include unsaturated 3 to 6 membered
hetero-monocyclic groups containing 1 to 4 nitrogen atoms, such as
pyrrolyl, pyridyl, pyrimidyl, and pyrazinyl; unsaturated condensed
heterocyclic groups containing 1 to 5 nitrogen atoms, such as
indolyl, quinolyl and isoquinolyl; unsaturated 3 to 6-membered
hetero-monocyclic groups containing an oxygen atom, such as furyl;
unsaturated 3 to 6 membered hetero-monocyclic groups containing a
sulfur atom, such as thienyl; unsaturated 3 to 6 membered
hetero-monocyclic groups containing 1 to 2 oxygen atoms and 1 to 3
nitrogen atoms, such as oxazolyl; unsaturated condensed
heterocyclic groups containing 1 to 2 oxygen atoms and 1 to 3
nitrogen atoms, such as benzoxazolyl; unsaturated 3 to 6 membered
hetero-monocyclic groups containing 1 to 2 sulfur atoms and 1 to 3
nitrogen atoms, such as thiazolyl; and unsaturated condensed
heterocyclic group containing 1 to 2 sulfur atoms and 1 to 3
nitrogen atoms, such as benzothiazolyl. The term "heteroaryl" also
includes unsaturated heterocyclic radicals, wherein "heterocyclic"
is as previously described, in which the heterocyclic group is
fused with an aryl group, in which aryl is as previously described.
Exemplary fused radicals include benzofuran, benzodioxole and
benzothiophene.
[0101] As used herein, the term "heterocyclicC.sub.1-4alkyl",
"heteroaromaticC.sub.1-4alkyl" and the like refer to the ring
structure bonded to a C.sub.1-4 alkyl radical.
[0102] All of the cyclic ring structures disclosed herein can be
attached at any point where such connection is possible, as
recognized by one skilled in the art.
[0103] As used herein, the term "patient" includes a human or an
animal such as a companion animal or livestock.
[0104] As used herein, the term "halogen" includes fluoride,
bromide, chloride, iodide or alabamide.
[0105] The invention disclosed herein is meant to encompass all
pharmaceutically acceptable salts thereof of the disclosed
compounds. The pharmaceutically acceptable salts include, but are
not limited to, metal salts such as sodium salt, potassium salt,
cesium salt and the like; alkaline earth metals such as calcium
salt, magnesium salt and the like; organic amine salts such as
triethylamine salt, pyridine salt, picoline salt, ethanolamine
salt, triethanolamine salt, dicyclohexylamine salt,
N,N'-dibenzylethylenediamine salt and the like; inorganic acid
salts such as hydrochloride, hydrobromide, sulfate, phosphate and
the like; organic acid salts such as formate, acetate,
trifluoroacetate, maleate, fumarate, tartrate and the like;
sulfonates such as methanesulfonate, benzenesulfonate,
p-toluenesulfonate, and the like; amino acid salts such as
arginate, asparginate, glutamate and the like.
[0106] The invention disclosed herein is also meant to encompass
all prodrugs of the disclosed compounds. Prodrugs are considered to
be any covalently bonded carriers which release the active parent
drug in vivo.
[0107] The invention disclosed herein is also meant to encompass
the in vivo metabolic products of the disclosed compounds. Such
products may result for example from the oxidation, reduction,
hydrolysis, amidation, esterification and the like of the
administered compound, primarily due to enzymatic processes.
Accordingly, the invention includes compounds produced by a process
comprising contacting a compound of this invention with a mammal
for a period of time sufficient to yield a metabolic product
thereof. Such products typically are identified by preparing a
radiolabelled compound of the invention, administering it
parenterally in a detectable dose to an animal such as rat, mouse,
guinea pig, monkey, or to man, allowing sufficient time for
metabolism to occur and isolating its conversion products from the
urine, blood or other biological samples.
[0108] The invention disclosed herein is also meant to encompass
the disclosed compounds being isotopically-labelled by having one
or more atoms replaced by an atom having a different atomic mass or
mass number. Examples of isotopes that can be incorporated into the
disclosed compounds include isotopes of hydrogen, carbon, nitrogen,
oxygen, phosphorous, fluorine and chlorine, such as .sup.2H,
.sup.3H, .sup.13C, .sup.14C, .sup.15N, .sup.18O, .sup.17O,
.sup.31P, .sup.32P, .sup.35S, .sup.18F, and .sup.36Cl,
respectively. Some of the compounds disclosed herein may contain
one or more asymmetric centers and may thus give rise to
enantiomers, diastereomers, and other stereoisomeric forms. The
present invention is also meant to encompass all such possible
forms as well as their racemic and resolved forms and mixtures
thereof. When the compounds described herein contain olefinic
double bonds or other centers of geometric asymmetry, and unless
specified otherwise, it is intended to include both E and Z
geometric isomers. All tautomers are intended to be encompassed by
the present invention as well
[0109] As used herein, the term "stereoisomers" is a general term
for all isomers of individual molecules that differ only in the
orientation of their atoms in space. It includes enantiomers and
isomers of compounds with more than one chiral center that are not
mirror images of one another (diastereomers).
[0110] The term "chiral center" refers to a carbon atom to which
four different groups are attached.
[0111] The term "enantiomer" or "enantiomeric" refers to a molecule
that is nonsuperimposeable on its mirror image and hence optically
active wherein the enantiomer rotates the plane of polarized light
in one direction and its mirror image rotates the plane of
polarized light in the opposite direction.
[0112] The term "racemic" refers to a mixture of equal parts of
enantiomers and which is optically inactive.
[0113] The term "resolution" refers to the separation or
concentration or depletion of one of the two enantiomeric forms of
a molecule.
[0114] The term "modulate" as used herein with respect to the ORL-1
receptor means the mediation of a pharmacodynamic response (e.g.,
analgesia) in a subject from (i) inhibiting or activating the
receptor, or (ii) directly or indirectly affecting the normal
regulation of the receptor activity. Compounds which modulate the
receptor activity include agonists, antagonists, mixed
agonists/antagonists and compounds which directly or indirectly
affect regulation of the receptor activity.
[0115] Certain preferred compounds according to the invention of
formulae (I) and (IA) include: [0116]
1-[1-(naphth-2-yl-methyl)-4-piperidinyl]-2,1,3-benzothiadiazol-2,2-dione;
[0117]
1-[1-(p-phenylbenzyl)-4-piperidinyl]-2,1,3-benzothiadiazol-2,2-dio-
ne; [0118]
1-[1-(3,3-Bis(phenyl)propyl)-4-piperidinyl]-2,1,3-benzothiadiaz-
ol-2,2-dione; [0119]
1-[1-(p-benzyloxybenzyl)-4-piperidinyl]-2,1,3-benzothiadiazol-2,2-dione;
[0120]
1-[1-(4-propylcyclohexyl)-4-piperidinyl]-2,1,3-benzothiadiazol-2,2-
-dione; [0121]
1-[1-(5-methylhex-2-yl)-4-piperidinyl]-2,1,3-benzothiadiazol-2,2-dione;
[0122]
1-[1-[4-(2-propyl)-cyclohexyl]-4-piperidinyl]-2,1,3-benzothiadiazo-
l-2,2-dione; [0123]
1-[1-(cyclooctylmethyl)-4-piperidinyl]-2,1,3-benzothiadiazol-2,2-dione;
[0124]
1-[1-(1,2,3,4-tetrahydro-2-naphthyl)-4-piperidinyl]-2,1,3-benzothi-
adiazol-2,2-dione; [0125]
1-[1-(decahydro-2-naphthyl)-4-piperidinyl]-2,1,3-benzothiadiazol-2,2-dion-
e; [0126]
1-[1-(1,3,-dihydroinden-2-yl)-4-piperidinyl]-2,1,3-benzothiadiaz-
ol-2,2-dione; [0127]
1-[1-(cyclooctyl)-4-piperidinyl]-2,1,3-benzothiadiazol-2,2-dione;
[0128]
1-[1-(naphth-2-yl-methyl)-4-piperidinyl]-2,1,3-benzothiadiazin-2,2-dione;
[0129]
1-[1-(p-benzyloxybenzyl)-4-piperidinyl]-2,1,3-benzothiadiazin-2,2--
dione; [0130]
1-[1-(p-phenylbenzyl)-4-piperidinyl]-2,1,3-benzothiadiazin-2,2-dione;
[0131]
1-[1-(decahydro-2-naphthyl)-4-piperidinyl]-2,1,3-benzothiadiazin-2-
,2-dione; [0132]
1-[1-[4-(2-propyl)-cyclohexyl]-4-piperidinyl]-2,1,3-benzothiadiazin-2,2-d-
ione; [0133]
1-[1-(4-propylcyclohexyl)-4-piperidinyl]-2,1,3-benzothiadiazin-2,2-dione;
[0134]
1-[1-(benzyl)-4-piperidinyl]-2,1,3-benzothiadiazin-2,2-dione;
[0135]
1-[1-(10,11-Dihydro-5H-dibenzo[a,d]-cyclohepten-5-yl)-4-piperidiny-
l]-2,1,3-benzothiadiazin-2,2-dione; [0136] 1-[1-(1,2,3,4
tetrahydro-2-naphthyl)-4-piperidinyl]-2,1,3-benzothiadiazin-2,2-dione;
[0137]
1-[1-(5-methylhex-2-yl)-4-piperidinyl]-2,1,3-benzothiadiazin-2,2-d-
ione; [0138]
1-[1-(norbornan-2-yl)-4-piperidinyl]-2,1,3-benzothiadiazin-2,2-dione;
[0139]
1-[1-(cyclooctyl)-4-piperidinyl]-2,1,3-benzothiadiazin-2,2-dione;
[0140]
1-[1-(1,3-dihydroinden-2-yl)-4-piperidinyl]-2,1,3-benzothiadiazin--
2,2-dione; [0141]
1-[1-(3,3-Bis(phenyl)propyl)-4-piperidinyl]-2,1,3-benzothiadiazin-2,2-dio-
ne; and
[0142] pharmaceutically acceptable salts thereof and solvates
thereof.
[0143] Other preferred compounds of formula (I) include: [0144]
3-butyl-1-[1-[4-(2-propyl)-cyclohexyl]-4-piperidinyl]-2,1,3-benzothiadiaz-
in-2,2-dione; [0145]
3-acetamido-1-[1-[4-(2-propyl)-cyclohexyl]-4-piperidinyl]-2,1,3-benzothia-
diazin-2,2-dione; [0146]
3-(2-methanesulfonamido)-1-[1-[4-(2-propyl)-cyclohexyl]-4-piperidinyl]-2,-
1,3-benzothiadiazin-2,2-dione; [0147]
3-methoxycarbonylmethyl-1-[1-[4-(2-propyl)-cyclohexyl]-4-piperidinyl]-2,1-
,3-benzothiadiazin-2,2-dione; [0148]
3-cyanomethyl-1-[1-[4-(2-propyl)-cyclohexyl]-4-piperidinyl]-2,1,3-benzoth-
iadiazin-2,2-dione; [0149]
3-(2-hydroxyethyl)-1-[1-[4-(2-propyl)-cyclohexyl]-4-piperidinyl]-2,1,3-be-
nzothiadiazin-2,2-dione; [0150]
3-butoxycarbonylmethyl-1-[1-[4-(2-propyl)-cyclohexyl]-4-piperidinyl]-2,1,-
3-benzothiadiazin-2,2-dione; and
[0151] pharmaceutically acceptable salts thereof and solvates
thereof.
[0152] Certain preferred compounds according to the invention of
formula (II) and (IIA) include: [0153]
1,2,3,4-tetrahydro-1-[1-(naphth-2-yl-methyl)-4-piperidinyl]-quinolin-2-on-
e; [0154]
1,2,3,4-tetrahydro-1-[1-(p-phenylbenzyl)-4-piperidinyl]-quinolin-
-2-one; [0155]
1,2,3,4-tetrahydro-1-[1-[4,4-bis(4-fluorophenyl)butyl]-4-piperidinyl]-qui-
nolin-2-one; [0156]
1,2,3,4-tetrahydro-1-[1-(p-benzyloxybenzyl)-4-piperidinyl]-quinolin-2-one-
; [0157]
1,2,3,4-tetrahydro-1-[1-(1,2,3,4-tetrahydro-2-naphthyl)-4-piperid-
inyl]-quinolin-2-one-; [0158]
1,2,3,4-tetrahydro-1-[1-(4-propyl-cyclohexyl)-4-piperidinyl]-quinolin-2-o-
ne; [0159]
1,2,3,4-tetrahydro-1-[1-(5-methylhex-2-yl)-4-piperidinyl]-quino-
lin-2-one; [0160]
1,2,3,4-tetrahydro-1-[1-(norbornan-2-yl)-4-piperidinyl]-quinolin-2-one;
[0161]
1,2,3,4-tetrahydro-1-[1-(decahydro-2-naphthyl)-4-piperidinyl]-quin-
olin-2-one; [0162]
1,2,3,4-tetrahydro-1-[1-(10,11-dihydro-5H-dibenzo[a,d]-cyclohepten-5-yl)--
4-piperidinyl]-quinolin-2-one; [0163]
1,2,3,4-tetrahydro-1-[1-(3,3-diphenylpropyl)-4-piperidinyl]-quinolin-2-on-
e; [0164]
1,2,3,4-tetrahydro-1-[1-(cyclooctyl)-4-piperidinyl]-quinolin-2-o-
ne; [0165]
1,2,3,4-tetrahydro-1-[1-[4-(1-methylethyl)-cyclohexyl]-4-piperi-
dinyl]-quinolin-2-one; [0166]
1,2,3,4-tetrahydro-1-[1-(1,3-dihydroinden-2-yl)-4-piperidinyl]-quinolin-2-
-one; [0167]
1,2,3,4-tetrahydro-1-[1-(cyclooctylmethyl)-4-piperidinyl]-quinolin-2-one;
and
[0168] pharmaceutically acceptable salts thereof and solvates
thereof.
DETAILED DESCRIPTION OF THE INVENTION
[0169] The compounds of the present invention can be administered
to anyone requiring modulation of the opioid and ORL1 receptors.
Administration may be orally, topically, by suppository,
inhalation, or parenterally.
[0170] The present invention also encompasses all pharmaceutically
acceptable salts of the foregoing compounds. One skilled in the art
will recognize that acid addition salts of the presently claimed
compounds may be prepared by reaction of the compounds with the
appropriate acid via a variety of known methods.
[0171] Various oral dosage forms can be used, including such solid
forms as tablets, gelcaps, capsules, caplets, granules, lozenges
and bulk powders and liquid forms such as emulsions, solution and
suspensions. The compounds of the present invention can be
administered alone or can be combined with various pharmaceutically
acceptable carriers and excipients known to those skilled in the
art, including but not limited to diluents, suspending agents,
solubilizers, binders, disintegrants, preservatives, coloring
agents, lubricants and the like.
[0172] When the compounds of the present invention are incorporated
into oral tablets, such tablets can be compressed, tablet
triturates, enteric-coated, sugar-coated, film-coated, multiply
compressed or multiply layered. Liquid oral dosage forms include
aqueous and nonaqueous solutions, emulsions, suspensions, and
solutions and/or suspensions reconstituted from non-effervescent
granules, containing suitable solvents, preservatives, emulsifying
agents, suspending agents, diluents, sweeteners, coloring agents,
and flavoring agents. When the compounds of the present invention
are to be injected parenterally, they may be, e.g., in the form of
an isotonic sterile solution. Alternatively, when the compounds of
the present invention are to be inhaled, they may be formulated
into a dry aerosol or may be formulated into an aqueous or
partially aqueous solution.
[0173] In addition, when the compounds of the present invention are
incorporated into oral dosage forms, it is contemplated that such
dosage forms may provide an immediate release of the compound in
the gastrointestinal tract, or alternatively may provide a
controlled and/or sustained release through the gastrointestinal
tract. A wide variety of controlled and/or sustained release
formulations are well known to those skilled in the art, and are
contemplated for use in connection with the formulations of the
present invention. The controlled and/or sustained release may be
provided by, e.g., a coating on the oral dosage form or by
incorporating the compound(s) of the invention into a controlled
and/or sustained release matrix.
[0174] Specific examples of pharmaceutically acceptable carriers
and excipients that may be used to formulate oral dosage forms, are
described in the Handbook of Pharmaceutical Excipients, American
Pharmaceutical Association (1986). Techniques and compositions for
making solid oral dosage forms are described in Pharmaceutical
Dosage Forms: Tablets (Lieberman, Lachman and Schwartz, editors)
2nd edition, published by Marcel Dekker, Inc. Techniques and
compositions for making tablets (compressed and molded), capsules
(hard and soft gelatin) and pills are also described in Remington's
Pharmaceutical Sciences (Arthur Osol, editor), 1553B1593 (1980).
Techniques and composition for making liquid oral dosage forms are
described in Pharmaceutical Dosage Forms: Disperse Systems,
(Lieberman, Rieger and Banker, editors) published by Marcel Dekker,
Inc.
[0175] When the compounds of the present invention are incorporated
for parenteral administration by injection (e.g., continuous
infusion or bolus injection), the formulation for parenteral
administration may be in the form of suspensions, solutions,
emulsions in oily or aqueous vehicles, and such formulations may
further comprise pharmaceutically necessary additives such as
stabilizing agents, suspending agents, dispersing agents, and the
like. The compounds of the invention may also be in the form of a
powder for reconstitution as an injectable formulation.
[0176] In certain embodiments, the compounds of the present
invention can be used in combination with at least one other
therapeutic agent. Therapeutic agents include, but are not limited
to, .mu.-opioid agonists; non-opioid analgesics; non-steroid
antiinflammatory agents; Cox-II inhibitors; antiemetics;
.beta.-adrenergic blockers; anticonvulsants; antidepressants;
Ca2+-channel blockers; anticancer agent and mixtures thereof.
[0177] In certain embodiments, the compounds of the present
invention can be formulated in a pharmaceutical dosage form in
combination with a .mu.-opioid agonist. .mu.-opioid agonists, which
may be included in the formulations of the present invention
include but are not limited to include alfentanil, allylprodine,
alphaprodine, anileridine, benzylmorphine, bezitramide,
buprenorphine, butorphanol, clonitazene, codeine, desomorphine,
dextromoramide, dezocine, diampromide, diamorphone, dihydrocodeine,
dihydromorphine, dimenoxadol, dimepheptanol, dimethylthiambutene,
dioxaphetyl butyrate, dipipanone, eptazocine, ethoheptazine,
ethylmethylthiambutene, ethylmorphine, etonitazene fentanyl,
heroin, hydrocodone, hydromorphone, hydroxypethidine, isomethadone,
ketobemidone, levorphanol, levophenacylmorphan, lofentanil,
meperidine, meptazinol, metazocine, methadone, metopon, morphine,
myrophine, nalbuphine, narceine, nicomorphine, norlevorphanol,
normethadone, nalorphine, normorphine, norpipanone, opium,
oxycodone, oxymorphone, papavereturn, pentazocine, phenadoxone,
phenomorphan, phenazocine, phenoperidine, piminodine, piritramide,
proheptazine, promedol, properidine, propiram, propoxyphene,
sufentanil, tilidine, tramadol, pharmaceutically acceptable salts
thereof, and mixtures thereof.
[0178] In certain preferred embodiments, the .mu.-opioid agonist is
selected from codeine, hydromorphone, hydrocodone, oxycodone,
dihydrocodeine, dihydromorphine, morphine, tramadol, oxymorphone,
pharmaceutically acceptable salts thereof, and mixtures
thereof.
[0179] In another embodiment of the invention, the medicament
comprises a mixture of a Cox-II inhibitor and an inhibitor of
5-lipoxygenase for the treatment of pain and/or inflammation.
Suitable Cox-II inhibitors and 5-lipoxygenase inhibitors, as well
as combinations thereof are described in U.S. Pat. No. 6,136,839,
which is hereby incorporated by reference in its entirety. Cox-II
inhibitors include, but are not limited to rofecoxib (Vioxx),
celecoxib (Celebrex), DUP-697, flosulide, meloxicam, 6-MNA,
L-745337, nabumetone, nimesulide, NS-398, SC-5766, T-614, L-768277,
GR-253035, JTE-522, RS-57067-000, SC-58125, SC-078, PD-138387,
NS-398, flosulide, D-1367, SC-5766, PD-164387, etoricoxib,
valdecoxib and parecoxib or pharmaceutically acceptable salts,
enantiomers or tautomers thereof.
[0180] The compounds of the present invention can also be combined
in dosage forms with non-opioid analgesics, e.g., non-steroidal
anti-inflammatory agents, including aspirin, ibuprofen, diclofenac,
naproxen, benoxaprofen, flurbiprofen, fenoprofen, flubufen,
ketoprofen, indoprofen, piroprofen, carprofen, oxaprozin,
pramoprofen, muroprofen, trioxaprofen, suprofen, aminoprofen,
tiaprofenic acid, fluprofen, bucloxic acid, indomethacin, sulindac,
tolmetin, zomepirac, tiopinac, zidometacin, acemetacin, fentiazac,
clidanac, oxpinac, mefenamic acid, meclofenamic acid, flufenamic
acid, niflumic acid tolfenamic acid, diflurisal, flufenisal,
piroxicam, sudoxicam or isoxicam, pharmaceutically acceptable salts
thereof, and mixtures thereof. Other suitable non-opioid analgesics
which may be included in the dosage forms of the present invention
include the following, non-limiting, chemical classes of analgesic,
antipyretic, nonsteroidal antiinflammatory drugs: salicylic acid
derivatives, including aspirin, sodium salicylate, choline
magnesium trisalicylate, salsalate, diflunisal, salicylsalicylic
acid, sulfasalazine, and olsalazin; para-aminophennol derivatives
including acetaminophen; indole and indene acetic acids, including
indomethacin, sulindac, and etodolac; heteroaryl acetic acids,
including tolmetin, diclofenac, and ketorolac; anthranilic acids
(fenamates), including mefenamic acid, and meclofenamic acid;
enolic acids, including oxicams (piroxicam, tenoxicam), and
pyrazolidinediones (phenylbutazone, oxyphenthartazone); and
alkanones, including nabumetone. For a more detailed description of
the NSAIDs that may be included within the medicaments employed in
the present invention, see Paul A. Insel Analgesic-Antipyretic and
Antiinflammatory Agents and Drugs Employed in the treatment of Gout
in Goodman & Gilman's The Pharmacological Basis of
Therapeutics, 617-57 (Peny B. Molinhoff and Raymond W. Ruddon,
Eds., Ninth Edition, 1996), and Glen R. Hanson Analgesic,
Antipyretic and Anti-Inflammatory Drugs in Remington: The Science
and Practice of Pharmacy Vol II, 1196-1221 (A. R. Gennaro, Ed. 19th
Ed. 1995) which are hereby incorporated by reference in their
entireties.
[0181] In certain embodiments, the compounds of the present
invention can be formulated in a pharmaceutical dosage form in
combination with antimigraine agents. Antimigraine agents include,
but are not limited to, alpiropride, dihydroergotamine, dolasetron,
ergocornine, ergocorninine, ergocryptine, ergot, ergotamine,
flumedroxone acetate, fonazine, lisuride, lomerizine, methysergide
oxetorone, pizotyline, and mixtures thereof.
[0182] The other therapeutic agent can also be an adjuvant to
reduce any potential side effects such as, for example, an
antiemetic agent. Suitable antiemetic agents include, but are not
limited to, metoclopromide, domperidone, prochlorperazine,
promethazine, chlorpromazine, trimethobenzamide, ondansetron,
granisetron, hydroxyzine, acethylleucine monoethanolamine,
alizapride, azasetron, benzquinamide, bietanautine, bromopride,
buclizine, clebopride, cyclizine, dimenhydrinate, diphenidol,
dolasetron, meclizine, methallatal, metopimazine, nabilone,
oxyperndyl, pipamazine, scopolamine, sulpiride,
tetrahydrocannabinols, thiethylperazine, thioproperazine,
tropisetron, and mixtures thereof.
[0183] In certain embodiments, the compounds of the present
invention can be formulated in a pharmaceutical dosage form in
combination with .beta.-adrenergic blockers. Suitable
.beta.-adrenergic blockers include, but are not limited to,
acebutolol, alprenolol, amosulabol, arotinolol, atenolol,
befunolol, betaxolol, bevantolol, bisoprolol, bopindolol,
bucumolol, bufetolol, bufuralol, bunitrolol, bupranolol, butidrine
hydrochloride, butofilolol, carazolol, carteolol, carvedilol,
celiprolol, cetamolol, cloranolol, dilevalol, epanolol, esmolol,
indenolol, labetalol, levobunolol, mepindolol, metipranolol,
metoprolol, moprolol, nadolol, nadoxolol, nebivalol, nifenalol,
nipradilol, oxprenolol, penbutolol, pindolol, practolol,
pronethalol, propranolol, sotalol, sulfinalol, talinolol,
tertatolol, tilisolol, timolol, toliprolol, and xibenolol.
[0184] In certain embodiments, the compounds of the present
invention can be formulated in a pharmaceutical dosage form in
combination with anticonvulsants. Suitable anticonvulsants include,
but are not limited to, acetylpheneturide, albutoin, aloxidone,
aminoglutethimide, 4-amino-3-hydroxybutyric acid, atrolactamide,
beclamide, buramate, calcium bromide, carbamazepine, cinromide,
clomethiazole, clonazepam, decimemide, diethadione, dimethadione,
doxenitroin, eterobarb, ethadione, ethosuximide, ethotoin,
felbamate, fluoresone, gabapentin, 5-hydroxytryptophan,
lamotrigine, magnesium bromide, magnesium sulfate, mephenyloin,
mephobarbital, metharbital, methetoin, methsuximide,
5-methyl-5-(3-phenantlu-yl)-hydantoin, 3-methyl-5-phenylhydantoin,
narcobarbital, nimetazepam, nitrazepam, oxcarbazepine,
paramethadione, phenacemide, phenetharbital, pheneturide,
phenobarbital, phensuximide, phenylmethylbarbituric acid,
phenyloin, phethenylate sodium, potassium bromide, pregabaline,
primidone, progabide, sodium bromide, solanum, strontium bromide,
suclofenide, sulthiame, tetrantoin, tiagabine, topiramate,
trimethadione, valproic acid, valpromide, vigabatrin, and
zonisamide.
[0185] In certain embodiments, the compounds of the present
invention can be formulated in a pharmaceutical dosage form in
combination with antidepressants. Suitable antidepressants include,
but are not limited to, binedaline, caroxazone, citalopram,
dimethazan, fencamine, indalpine, indeloxazine hydrocholoride,
nefopam, nomifensine, oxitriptan, oxypertine, paroxetine,
sertraline, thiazesim, trazodone, benmoxine, iproclozide,
iproniazid, isocarboxazid, nialamide, octamoxin, phenelzine,
cotinine, rolicyprine, rolipram, maprotiline, metralindole,
mianserin, mirtazepine, adinazolam, amitriptyline,
amitriptylinoxide, amoxapine, butriptyline, clomipramine,
demexiptiline, desipramine, dibenzepin, dimetacrine, dothiepin,
doxepin, fluacizine, imipramine, imipramine N-oxide, iprindole,
lofepramine, melitracen, metapramine, nortriptyline, noxiptilin,
opipramol, pizotyline, propizepine, protriptyline, quinupramine,
tianeptine, trimipramine, adrafinil, benactyzine, bupropion,
butacetin, dioxadrol, duloxetine, etoperidone, febarbamate,
femoxetine, fenpentadiol, fluoxetine, fluvoxamine, hematoporphyrin,
hypericin, levophacetoperane, medifoxamine, milnacipran, minaprine,
moclobemide, nefazodone, oxaflozane, piberaline, prolintane,
pyrisuccideanol, ritanserin, roxindole, rubidium chloride,
sulpiride, tandospirone, thozalinone, tofenacin, toloxatone,
tranylcypromine, L-tryptophan, venlafaxine, viloxazine, and
zimeldine.
[0186] In certain embodiments, the compounds of the present
invention can be formulated in a pharmaceutical dosage form in
combination with Ca2+-channel blockers. Suitable Ca2+-channel
blockers include, but are not limited to, bepridil, clentiazem,
diltiazem, fendiline, gallopamil, mibefradil, prenylamine,
semotiadil, terodiline, verapamil, amlodipine, aranidipine,
barnidipine, benidipine, cilnidipine, efonidipine, elgodipine,
felodipine, isradipine, lacidipine, lercanidipine, manidipine,
nicardipine, nifedipine, nilvadipine, nimodipine, nisoldipine,
nitrendipine, cinnarizine, flunarizine, lidoflazine, lomerizine,
bencyclane, etafenone, fantofarone, and perhexyline.
[0187] In certain embodiments, the compounds of the present
invention can be formulated in a pharmaceutical dosage form in
combination with anticancer agents. Suitable anticancer agents
include, but are not limited to, acivicin; aclarubicin; acodazole
hydrochloride; acronine; adozelesin; aldesleukin; altretamine;
ambomycin; ametantrone acetate; aminoglutethimide; amsacrine;
anastrozole; antlramycin; asparaginase; asperlin; azacitidine;
azetepa; azotomycin; batimastat; benzodepa; bicalutamide;
bisantrene hydrochloride; bisnafide dimesylate; bizelesin;
bleomycin sulfate; brequinar sodium; bropirimine; busulfan;
cactinomycin; calusterone; caracemide; carbetimer; carboplatin;
carmustine; carubicin hydrochloride; carzelesin; cedefingol;
chlorambucil; cirolemycin; cisplatin; cladribine; crisnatol
mesylate; cyclophosphamide; cytarabine; dacarbazine; dactinomycin;
daunorubicin hydrochloride; decitabine; dexormaplatin; dezaguanine;
dezaguanine mesylate; diaziquone; docetaxel; doxorubicin;
doxorubicin hydrochloride; droloxifene; droloxifene citrate;
dromostanolone propionate; duazomycin; edatrexate; eflornithine
hydrochloride; elsamitrucin; enloplatin; enpromate; epipropidine;
epirubicin hydrochloride; erbulozole; esorubicin hydrochloride;
estramustine; estramustine phosphate sodium; etanidazole;
etoposide; etoposide phosphate; etoprine; fadrozole hydrochloride;
fazarabine; fenretinide; floxuridine; fludarabine phosphate;
fluorouracil; fluorocitabine; fosquidone; fostriecin sodium;
gemcitabine; gemcitabine hydrochloride; hydroxyurea; idarubicin
hydrochloride; ifosfamide; ilmofosine; interleukin II (including
recombinant interleukin II, or rIL2), interferon alfa-2a;
interferon alfa-2b; interferon alfa-n1; interferon alfa-n3;
interferon beta-I a; interferon gamma-I b; iproplatin; irinotecan
hydrochloride; lanreotide acetate; letrozole; leuprolide acetate;
liarozole hydrochloride; lometrexol sodium; lomustine; losoxantrone
hydrochloride; masoprocol; maytansine; mechlorethamine
hydrochloride; megestrol acetate; melengestrol acetate; melphalan;
menogaril; mercaptopurine; methotrexate; methotrexate sodium;
metoprine; meturedepa; mitindomide; mitocarcin; mitocromin;
mitogillin; mitomalcin; mitomycin; mitosper; mitotane; mitoxantrone
hydrochloride; mycophenolic acid; nocodazole; nogalamycin;
ormaplatin; oxisuran; paclitaxel; pegaspargase; peliomycin;
pentamustine; peplomycin sulfate; perfosfamide; pipobroman;
piposulfan; piroxantrone hydrochloride; plicamycin; plomestane;
porfimer sodium; porfiromycin; prednimustine; procarbazine
hydrochloride; puromycin; puromycin hydrochloride; pyrazofurin;
riboprine; rogletimide; safingol; safingol hydrochloride;
semustine; simtrazene; sparfosate sodium; sparsomycin;
spirogermanium hydrochloride; spiromustine; spiroplatin;
streptonigrin; streptozocin; sulofenur; talisomycin; tecogalan
sodium; tegafur; teloxantrone hydrochloride; temoporfin;
teniposide; teroxirone; testolactone; thiamiprine; thioguanine;
thiotepa; tiazofurin; tirapazamine; toremifene citrate; trestolone
acetate; triciribine phosphate; trimetrexate; trimetrexate
glucuronate; triptorelin; tubulozole hydrochloride; uracil mustard;
uredepa; vapreotide; verteporfin; vinblastine sulfate; vincristine
sulfate; vindesine; vindesine sulfate; vinepidine sulfate;
vinglycinate sulfate; vinleurosine sulfate; vinorelbine tartrate;
vinrosidine sulfate; vinzolidine sulfate; vorozole; zeniplatin;
zinostatin; zorubicin hydrochloride. Other anti-cancer drugs
include, but are not limited to: 20-epi-1,25 dihydroxyvitamin D3;
5-ethynyluracil; abiraterone; aclarubicin; acylfulvene; adecypenol;
adozelesin; aldesleukin; ALL-TK antagonists; altretamine;
ambamustine; amidox; amifostine; aminolevulinic acid; amrubicin;
amsacrine; anagrelide; anastrozole; andrographolide; angiogenesis
inhibitors; antagonist D; antagonist G; antarelix; anti-dorsalizing
morphogenetic protein-1; antiandrogen, prostatic carcinoma;
antiestrogen; antineoplaston; antisense oligonucleotides;
aphidicolin glycinate; apoptosis gene modulators; apoptosis
regulators; apurinic acid; ara-CDP-DL-PTBA; arginine deaminase;
asulacrine; atamestane; atrimustine; axinastatin 1; axinastatin 2;
axinastatin 3; azasetron; azatoxin; azatyrosine; baccatin III
derivatives; balanol; batimastat; BCR/ABL antagonists;
benzochlorins; benzoylstaurosporine; beta lactam derivatives;
beta-alethine; betaclamycin B; betulinic acid; bFGF inhibitor;
bicalutamide; bisantrene; bisaziridinylspermine; bisnafide;
bistratene A; bizelesin; breflate; bropirimine; budotitane;
buthionine sulfoximine; calcipotriol; calphostin C; camptothecin
derivatives; canarypox IL-2; capecitabine;
carboxamide-amino-triazole; carboxyamidotriazole; CaRest M3; CARN
700; cartilage derived inhibitor; carzelesin; casein kinase
inhibitors (ICOS); castanospermine; cecropin B; cetrorelix;
chlorlns; chloroquinoxaline sulfonamide; cicaprost; cis-porphyrin;
cladribine; clomifene analogues; clotrimazole; collismycin A;
collismycin B; combretastatin A4; combretastatin analogue;
conagenin; crambescidin 816; crisnatol; cryptophycin 8;
cryptophycin A derivatives; curacin A; cyclopentantlraquinones;
cycloplatam; cypemycin; cytarabine ocfosfate; cytolytic factor;
cytostatin; dacliximab; decitabine; dehydrodidemnin B; deslorelin;
dexamethasone; dexifosfamide; dexrazoxane; dexverapamil;
diaziquone; didemnin B; didox; diethylnorspermine;
dihydro-5-azacytidine; dihydrotaxol, 9-; dioxamycin; diphenyl
spiromustine; docetaxel; docosanol; dolasetron; doxifluridine;
droloxifene; dronabinol; duocarmycin SA; ebselen; ecomustine;
edelfosine; edrecolomab; eflornithine; elemene; emitefur;
epirubicin; epristeride; estramustine analogue; estrogen agonists;
estrogen antagonists; etanidazole; etoposide phosphate; exemestane;
fadrozole; fazarabine; felmetinide; filgrastim; finasteride;
flavopiridol; flezelastine; fluasterone; fludarabine;
fluorodaunorunicin hydrochloride; forfenimex; formestane;
fostriecin; fotemustine; gadolinium texaphyrin; gallium nitrate;
galocitabine; ganirelix; gelatinase inhibitors; gemcitabine;
glutathione inhibitors; hepsulfam; heregulin; hexamethylene
bisacetamide; hypericin; ibandronic acid; idarubicin; idoxifene;
idramantone; ilmofosine; ilomastat; imidazoacridones; imiquimod;
immunostimulan-t peptides; insulin-like growth factor-1 receptor
inhibitor; interferon agonists; interferons; interleukins;
iobenguane; iododoxorubicin; ipomeanol, 4-; iroplact; irsogladine;
isobengazole; isohomohalicondrin B; itasetron; jasplakinolide;
kahalalide F; lamellarin-N triacetate; lanreotide; leinamycin;
lenograstim; lentinan sulfate; leptolstatin; letrozole; leukemia
inhibiting factor; leukocyte alpha interferon;
leuprolide+estrogen+progesterone; leuprorelin; levamisole;
liarozole; linear polyamine analogue; lipophilic disaccharide
peptide; lipophilic platinum compounds; lissoclinamide 7;
lobaplatin; lombricine; lometrexol; lonidamine; losoxantrone;
lovastatin; loxoribine; lurtotecan; lutetium texaphyrin;
lysofylline; lytic peptides; maitansine; mannostatin A; marimastat;
masoprocol; maspin; matrilysin inhibitors; matrix metalloproteinase
inhibitors; menogaril; merbarone; meterelin; methioninase;
metoclopramide; MIF inhibitor; mifepristone; miltefosine;
mirimostim; mismatched double stranded RNA; mitoguazone;
mitolactol; mitomycin analogues; mitonafide; mitotoxin fibroblast
growth factor-saporin; mitoxantrone; mofarotene; molgramostim;
monoclonal antibody, human chorionic gonadotrophin; monophosphoryl
lipid A+myobacterium cell wall sk; mopidamol; multiple drug
resistance gene inhibitor; multiple tumor suppressor 1-based
therapy; mustard anticancer agent; mycaperoxide B; mycobacterial
cell wall extract; myriaporone; N-acetyldinaline; N-substituted
benzamides; nafarelin; nagrestip; naloxone+pentazocine; napavin;
naphterpin; nartograstim; nedaplatin; nemorubicin; neridronic acid;
neutral endopeptidase; nilutamide; nisamycin; nitric oxide
modulators; nitroxide antioxidant; nitrullyn; O6-benzylguanine;
octreotide; okicenone; oligonucleotides; onapristone; ondansetron;
ondansetron; oracin; oral cytokine inducer; ormaplatin; osaterone;
oxaliplatin; oxaunomycin; paclitaxel; paclitaxel analogues;
paclitaxel derivatives; palauamine; palmitoylrhizoxin; pamidronic
acid; panaxytriol; panomifene; parabactin; pazelliptine;
pegaspargase; peldesine; pentosan polysulfate sodium; pentostatin;
pentrozole; perflubron; perfosfamide; perillyl alcohol;
phenazinomycin; phenylacetate; phosphatase inhibitors; picibanil;
pilocarpine hydrochloride; pirarubicin; piritrexim; placetin A;
placetin B; plasminogen activator ihlaibitor; platinum complex;
platinum compounds; platinum-triamine complex; porfimer sodium;
porfiromycin; prednisone; propyl bis-acridone; prostaglandin J2;
proteasome inhibitors; protein A-based immune modulator; protein
kinase C inhibitor; protein kinase C inhibitors, microalgal;
protein tyrosine phosphatase inhibitors; purine nucleoside
phosphorylase ihliibitors; purpurins; pyrazoloacridine;
pyridoxylated hemoglobin polyoxyethylene conjugate; raf
antagonists; raltitrexed; ramosetron; ras farnesyl protein
transferase inhibitors; ras inhibitors; ras-GAP inhibitor;
retelliptine demethylated; rhenium Re 186 etidronate; rhizoxin;
ribozymes; RII retinamide; rogletimide; rohitukine; romurtide;
roquinimex; rubiginone B1; ruboxyl; safingol; saintopin; SarCNU;
sarcophytol A; sargramostim; Sdi 1 mimetics; semustine; senescence
derived inhibitor 1; sense oligonucleotides; signal transduction
inhibitors; signal transduction modulators; single chain antigen
binding protein; sizofuran; sobuzoxane; sodium borocaptate; sodium
phenylacetate; solverol; somatomedin binding protein; sonermin;
sparfosic acid; spicamycin D; spiromustine; splenopentin;
spongistatin 1; squalamine; stem cell inhibitor; stem-cell division
inhibitors; stipiamide; stromelysin inhibitors; sulfinosine;
superactive vasoactive intestinal peptide antagonist; suradista;
suramin; swainsonine; synthetic glycosaminoglycans; tallimustine;
tamoxifen methiodide; tauromustine; tazarotene; tecogalan sodium;
tegafur; tellurapyrylium; telomerase inhibitors; temoporfin;
temozolomide; teniposide; tetrachlorodecaoxide; tetrazomine;
thaliblastine; thiocoraline; thirombopoietin; thrombopoietin
mimetic; thymalfasin; thymopoietin receptor agonist; thymotrinan;
thyroid stimulating hormone; tin ethyl etiopurpurin; tirapazamine;
titanocene bichloride; topsentin; toremifene; totipotent stem cell
factor; translation inhibitors; tretinoin; triacetyluridine;
triciribine; trimetrexate; triptorelin; tropisetron; turosteride;
tyrosine kinase inhibitors; tyrphostins; UBC inhibitors; ubenimex;
urogenital sinus-derived growth inhibitory factor; urokinase
receptor antagonists; vapreotide; variolin B; vector system,
erythrocyte gene therapy; velaresol; veramine; verdins;
verteporfin; vinorelbine; vinxaltine; vitaxin; vorozole;
zanoterone; zeniplatin; zilascorb; and zinostatin stimalamer.
[0188] The compounds of the present invention and the other
therapeutic agent can act additively or, more preferably,
synergistically. In a preferred embodiment, a composition
comprising a compounds of the present invention is administered
concurrently with the administration of another therapeutic agent,
which can be part of the same composition or in a different
composition from that comprising the compounds of the present
invention. In another embodiment, a composition comprising the
compounds of the present invention is administered prior to or
subsequent to administration of another therapeutic agent.
[0189] The compounds of the present invention when administered,
e.g., via the oral, parenteral or topical routes to mammals, can be
in a dosage in the range of about 0.01 mg/kg to about 3000 mg/kg
body weight of the patient per day, preferably about 0.01 mg/kg to
about 1000 mg/kg body weight per day administered singly or as a
divided dose. However, variations will necessarily occur depending
upon the weight and physical condition (e.g., hepatic and renal
function) of the subject being treated, the affliction to be
treated, the severity of the symptoms, the route of administration,
the frequency of the dosage interval, the presence of any
deleterious side-effects, and the particular compound utilized,
among other things.
[0190] The compounds of the present invention preferably have a
binding affinity K.sub.i for the human ORL-1 receptor of about 500
nM or less; 100 nM or less; 50 nM or less; 20 nM or less or 5 nM or
less. The binding affinity K.sub.i can be measured by one skilled
in the art by an assay utilizing membranes from recombinant HEK-293
cells expressing the human opioid receptor-like receptor (ORL-1) as
described below.
[0191] The following examples illustrate various aspects of the
present invention, and are not to be construed to limit the claims
in any manner whatsoever.
Example 1
Synthesis of "5-Membered SO.sub.2" Head Groups
##STR00013##
[0192] Procedure:
[0193] 1,2-Phenylenediamine 1 (160 g, 1.50 mol) and
4-oxo-piperidine-tert-butylester 2 (100 g, 0.50 mol) were dissolved
in 1,2-dichloroethane (2.0 L) with stirring. Acetic acid (31.6 mL)
was added, followed by sodium triacetoxyborohydride (148 g, 0.70
mol) and the resulting mixture stirred at room temperature for 18
hr. The solvent was evaporated and the residue partitioned between
ether and 1 M acetic acid. The organic layer was separated and
washed with 1M acetic acid (3.times.) followed by sodium
bicarbonate solution (1.times.). The aqueous phases were back
extracted with ether (1.times.) and the combined organic extracts
dried over MgSO.sub.4, filtered and the solvent evaporated to give
an orange gum. Addition of 600 mL of ether/hexane (1:1) followed by
seeding induced crystallization. After 15 min. the mixture was
filtered, washed with 300 mL of ether/hexane (1:1) to give pure 3
as a white solid (79.2 g, 53%).
[0194] m.p.=107.1-107.6.degree. C. .sup.1H-NMR (CDCl.sub.3): d 1.30
(bd, 2H), 1.40 (s, 9H), 1.95 (bd, 2H), 3.90 (bt, 2H), 3.25 (b, 2H),
3.30 (m, 1H), 3.95 (b, 2H), 6.60-6.80 (m, 4H).
[0195] The diamine 3 (5.4 g, 18.6 mmol) was dissolved in dry
pyridine (30 mL). Sulfamide (3.58 g, 37.2 mmol) was added and the
mixture heated to reflux for 2 h. The mixture was cooled to room
temperature and the solvent evaporated to dryness. The residue was
partitioned between dichloromethane:methanol (10:1, 500 mL) and 0.1
M hydrochloric acid (500 mL), the organic phase separated, washed
with brine (500 mL), dried over MgSO.sub.4, filtered and the
solvent evaporated. The residue was triturated with ethyl acetate
to give pure 4 as a pale pink solid (5.15 g, 79%).
[0196] m.p.=204.7.degree.-205.4.degree. C. .sup.1H-NMR (DMSO): d
1.30 (s, 9H), 1.80-1.95 (m, 4H), 2.80 (b, 2H), 3.95 (m, 2H), 4.10
(m, 1H), 6.70-7.00 (m, 4H), 11.25 (bs, 1H).
[0197] Compound 4 (5.15 g, 14.57 mmol) was suspended in 100 mL of
ethyl acetate, 20 mL of a 1:1 mixture of concentrated hydrochloric
acid/ethyl acetate was added and the suspension stirred at room
temperature for 2 h. The mixture was filtered and the filtrate
washed with ethyl acetate to give pure 5 (HCl salt) as a pale pink
solid (3.82 g, 91%).
[0198] .sup.1H-NMR (DMSO) (HCl salt): d 2.10 (m, 2H), 2.50 (m, 2H),
3.12 (m, 2H), 3.52 (m, 2H), 4.40 (m, 1H), 5.80 (b, 1H), 6.90-7.20
(m, 3H), 7.35 (m, 1H), 9.20 (b, 1H), 9.40 (b, 1H), 11.70 (b, 1H).
Elemental analysis:
C.sub.11H.sub.15N.sub.3O.sub.2S.HCl.0.75H.sub.2O requires: C,
43.56; H, 5.81; N, 13.85. found: C, 43.90; H, 5.78; N, 13.51.
Example 2
Synthesis of "6-Membered SO.sub.2" Head Groups
##STR00014##
[0199] Procedure:
[0200] Anthranilamide 6 (15.0 g, 110.1 mmol) and
N-benzyl-4-piperidone (20.96 g, 110.1 mmol) were dissolved in
glacial acetic acid (150 mL) with stirring under nitrogen over 15
min. Sodium triacetoxyborohydride (35.14 g, 165.8 mmol) was added
in portions and the resulting mixture stirred at room temperature
for 60 hr. The mixture was poured into water and extracted with
ethyl acetate (1.times.). The ethyl acetate extract was back
extracted with water (3.times.). The combined aqueous extracts were
carefully basified with sodium hydroxide pellets to pH 12 and the
mixture filtered to give a white solid that was triturated with
acetone to give 7 as a white crystalline solid (19.8 g, 58%).
[0201] mp=249.8-250.7.degree. C. (dec.).
[0202] To a suspension of lithium aluminium hydride (3.58 g, 96.7
mmol) in 50 mL of dry dioxane was added dropwise a suspension of 7
(10.0 g, 32.3 mmol) in 100 mL of dry dioxane. The resulting mixture
was stirred for 1 hr at room temperature then heated to reflux
overnight. The mixture was cooled to room temperature and
cautiously quenched with water over 1 hr. Magnesium sulfate (ca 20
g) was added, the mixture filtered through Celite, and the filter
cake washed with dichloromethane. The filtrate was dried over
MgSO.sub.4, filtered and evaporated. The residue was triturated
with ether to give pure 8 as a white solid (6.70 g, 71%).
[0203] mp=116-118.degree. C. .sup.1H-NMR (CDCl.sub.3): d 1.60 (m,
2H), 2.10 (m, 2H), 2.25 (bt, 2H), 2.85 (b, 2H), 3.40 (m, 1H), 3.60
(s, 2H), 3.91 (s, 2H), 6.63 (m, 2H), 7.05 (d, 1H), 7.20 (m, 1H),
7.25-7.4 (m, 5H).
[0204] To a solution of 8 (7.00 g, 23.7 mmol) in 50 mL of pyridine
was added sulfamide (4.55 g, 47.4 mmol) and the resulting solution
heated to reflux for 18 hr. After cooling to room temperature the
mixture was evaporated to give a brown gum. This was partitioned
between chloroform and 1M potassium carbonate solution and the
organic phase separated. The aqueous phase was extracted with
chloroform (2.times.) and the combined organic extracts dried over
MgSO.sub.4, filtered and evaporated. The residue was
chromatographed to give a pale yellow foam (6.00 g). This was
dissolved in 60 mL of ethyl acetate and 4 mL of a 1:1 mixture of
concentrated hydrochloric acid: ethyl acetate was added. The
mixture was allowed to stand for 30 min until complete
crystallization had occurred. The mixture was filtered and the
solid washed with ethyl acetate to give pure 9 as a white
crystalline solid (6.28 g, 67%).
[0205] mp=248-249.9.degree. C. .sup.1H-NMR (DMSO) (HCl salt): d
2.05 (m, 2H), 2.32 (m, 2H), 3.12 (m, 2H), 3.40 (b, 2H), 4.30 (b,
3H), 4.45 (b, 2H), 7.10-7.30 (m, 4H), 7.40-7.60 (m, 5H), 7.85 (m,
1H).
[0206] Compound 9 (4.0 g, 11 mmol) was hydrogenated over Pd/C in
100 mL of methanol/water (3:1) for 24 hr. Filtration and
evaporation gave a residue that was triturated with ethyl
acetate/methanol (1:1) to give pure 10 as a white crystalline solid
(2.72 g, 89%).
[0207] MS: m/z 268.1 (M+1). .sup.1H-NMR (CDCl.sub.3) (HCl salt): d
2.00 (m, 4H), 2.70 (m, 2H), 3.2 (m, 2H), 4.15 (m, 1H), 4.52 (s,
2H), 7.15-7.35 (m, 5H). Elemental analysis:
C.sub.12H.sub.17N.sub.3O.sub.2S.HCl.0.4H.sub.2O requires: C, 46.34;
H, 6.09; N, 13.51. found: C, 46.36; H, 5.88; N, 13.37.
Example 3
[0208] Attachments of Tail Groups to the "5-Membered SO.sub.2" and
"6-Membered SO.sub.2" Head Groups
[0209] Tail groups were attached to the head groups according to
the following procedures:
##STR00015##
General Procedure for Alkylation:
[0210] To a solution of the amine (1 eq) and triethylamine (1 eq)
in dimethylformamide, was added 1 eq of alkyl bromide or chloride
in one portion. The mixture was stirred and heated at 80.degree. C.
over night. TLC indicated the reaction was complete. The reaction
was quenched by the addition of water followed by 1 N NaOH to pH
10. The mixture was extracted 2.times. with Et.sub.2O. The combined
organic extracts were dried over potassium carbonate and the
solvent evaporated, followed by chromatography to give the pure
product.
General Procedure for Reductive Amination:
[0211] To a mixture of ketone or aldehyde (1 eq), amine (1 eq), and
acetic acid (1 eq) in methanol, was added sodium cyanoborohydride
(1.4 eq) in one portion. The mixture was stirred over night at room
temperature. TLC indicated the reaction was complete. The reaction
was quenched by the addition of water followed by 1 N NaOH to pH
10. The mixture was extracted 2.times. with Et.sub.2O. The combined
organic extracts were dried over potassium carbonate and the
solvent evaporated, followed by chromatography to give the pure
product. The following compounds were prepared by attaching the
tail groups using the general procedures described:
1-[1-(naphth-2-yl-methyl)-4-piperidinyl]-2,1,3-benzothiadiazol-2,2-dione
[0212] LC: 93.2%. MS: m/z 394.2 (M+1). .sup.1H-NMR (DMSO): d 1.95
(b, 2H), 2.22 (m, 2H), 2.40 (b, 2H), 3.10 (m, 2H), 3.80-4.00 (b,
3H), 6.60-6.80 (m, 4H), 7.50 (m, 3H), 7.90 (m, 4H), 10.8 (b,
1H).
1-[1-(p-phenylbenzyl)-4-piperidinyl]-2,1,3-benzothiadiazol-2,2-dione
[0213] LC: 96.4%. MS: m/z 420.6 (M+1). .sup.1H-NMR (CDCl.sub.3): d
2.07 (m, 2H), 2.30 (m, 2H), 2.48 (m, 2H), 3.15 (m, 2H), 3.65 (s,
2H), 3.90 (m, 1H), 6.78-6.95 (m, 4H), 7.30-7.60 (m, 9H).
1-[1-(3,3-Bis(phenyl)propyl)-4-piperidinyl]-2,1,3-benzothiadiazol-2,2-dion-
e
[0214] LC: 100%. MS: m/z 448.2 (M+1). .sup.1H-NMR (DMSO): d 2.00
(b, 2H), 2.20-2.40 (m, 4H), 2.60-2.85 (m, 4H), 3.20-3.50 (m, 2H),
3.90 (bt, 1H), 4.00 (t, 1H), 6.40-6.60 (m, 4H), 7.18 (m, 2H),
7.25-7.40 (m, 8H).
1-[1-(p-benzyloxybenzyl)-4-piperidinyl]-2,1,3-benzothiadiazol-2,2-dione
[0215] LC: 98%. MS: m/z 450.7 (M+1). .sup.1H-NMR (CDCl.sub.3): d
2.23 (m, 2H), 2.75 (m, 2H), 2.90 (m, 2H), 3.62 (s, 2H), 3.85 (m,
2H), 4.12 (m, 1H), 5.10 (s, 2H), 6.90-7.48 (m, 13H).
1-[1-(1,2,3,4-tetrahydro-2-naphthyl)-4-piperidinyl]-2,1,3-benzothiadiazol--
2,2-dione
[0216] LC: 100%. MS: m/z 384.6 (M+1). .sup.1H-NMR (DMSO-d.sub.6): d
1.20-2.60 (m, 10H), 2.75-3.10 (m, 5H), 3.90 (m, 1H), 6.40 (b, 2H),
6.55 (b, 2H), 7.10 (b, 4H).
1-[1-(4-propylcyclohexyl)-4-piperidinyl]-2,1,3-benzothiadiazol-2,2-dione
[0217] LC: 92.7%. MS: m/z 378.3 (M+1). .sup.1H-NMR (DMSO-d.sub.6):
d 0.85 (t, 3H), 1.15 (m, 1H), 1.30 (m, 4H), 1.35-1.55 (m, 2H),
1.55-1.65 (m, 4H), 1.70 (b, 1H), 1.85 (b, 1H), 1.90-2.10 (m, 2H),
2.35-2.50 (b, 2H), 3.00 (b, 3H), 3.55 (b, 2H), 3.92 (m, 1H), 6.30
(m, 2H), 6.50 (m, 2H), 10.1 (b, 1H).
1-[1-(5-methylhex-2-yl)-4-piperidinyl]-2,1,3-benzothiadiazol-2,2-dione
[0218] LC: 100%. MS: m/z 352.3 (M+1). .sup.1H-NMR (DMSO): d 0.85
(m, 6H), 1.10-1.30 (m, 6H), 1.40 (m, 1H), 1.50 (m, 1H), 1.70 (b,
1H), 2.05 (bd, 2H), 2.45 (m, 2H), 2.90-3.20 (m, 3H), 3.90-4.10 (m,
2H), 6.30 (m, 2H), 6.50 (m, 2H).
1-[1-(decahydro-2-naphthyl)-4-piperidinyl]-2,1,3-benzothiadiazol-2,2-dione
[0219] LC: 95%. MS: m/z 390.7 (M+1). .sup.1H-NMR (DMSO-d.sub.6): d
0.8-2.10 (m, 20H), 2.90-3.60 (m, 5H), 3.95 (m, 11H), 6.30 (b, 2H),
6.50 (b, 2H).
1-[1-(cyclooctyl)-4-piperidinyl]-2,1,3-benzothiadiazol-2,2-dione
[0220] LC: 100%. MS: m/z 364.3 (M+1). .sup.1H-NMR (DMSO-d.sub.6): d
1.30-2.10 (m, 18H), 2.35-2.55 (m, 2H), 2.90-3.40 (m, 3H), 4.00 (m,
1H), 6.30 (m, 2H), 6.50 (m, 2H).
1-[1-[4-(2-propyl)-cyclohexyl]-4-piperidinyl]-2,1,3-benzothiadiazol-2,2-di-
one
[0221] LC: 95.1%. MS: m/z 378.3 (M+1). .sup.1H-NMR (DMSO-d.sub.6):
d 0.80-0.95 (m, 6H), 1.03 (b, 1H), 1.15 (m, 1H), 1.30-1.50 (m, 2H),
1.55-1.90 (m, 6H), 2.05 (b, 2H), 2.30-2.50 (m, 2H), 2.80-3.20 (b,
3H), 3.40-3.60 (b, 2H), 3.95 (m, 1H), 6.38 (m, 2H), 6.45 (m, 2H),
7.00 (b, 1H).
1-[1-(1,3,-dihydroinden-2-yl)-4-piperidinyl]-2,1,3-benzothiadiazol-2,2-dio-
ne
[0222] LC: 96.5%. MS: m/z 370.6 (M+1). .sup.1H-NMR (DMSO-d.sub.6):
d 2.00 (b, 2H), 2.30 (m, 2H), 2.70 (m, 2H), 3.10 (m, 2H), 3.20-3.60
(m, 5H), 3.90 (m, 1H), 6.40-6.65 (m, 4H), 7.10-7.30 (m, 4H).
1-[1-(cyclooctylmethyl)-4-piperidinyl]-2,1,3-benzothiadiazol-2,2-dione
[0223] LC: 100%. MS: m/z 392.7 (M+15). .sup.1H-NMR (MeOH): d
1.30-1.80 (m, 14H), 2.05 (m, 1H), 2.22 (m, 2H), 2.50 (m, 2H), 2.85
(m, 2H), 3.00 (m, 2H), 3.60 (m, 2H), 4.30 (m, 1H), 4.50 (s, 2H),
7.10-7.40 (m, 4H).
1-[1-(benzyl)-4-piperidinyl]-2,1,3-benzothiadiazin-2,2-dione
[0224] .sup.1H-NMR (DMSO-d.sub.6) of HCl Salt form: d 2.05 (m, 2H),
2.32 (m, 2H), 3.12 (m, 2H), 3.40 (b, 2H), 4.30 (b, 3H), 4.45 (b,
2H), 7.10-7.30 (m, 4H), 7.40-7.60 (m, 5H), 7.85 (m, 1H).
1-[1-(naphth-2-yl-methyl)-4-piperidinyl]-2,1,3-benzothiadiazin-2,2-dione
[0225] LC: 100%. MS: m/z 408.3 (M+1) .sup.1H-NMR (CDCl.sub.3): d
1.95 (b, 2H), 2.20 (m, 4H), 3.05 (m, 2H), 3.70 (s, 2H), 4.10 (m,
1H), 4.50 (s, 2H), 7.10 (m, 2H), 7.20 (m, 1H), 7.30 (m, 1H), 7.45
(m, 3H), 7.75 (s, 1H), 7.85 (m, 3H).
1-[1-(p-phenylbenzyl)-4-piperidinyl]-2,1,3-benzothiadiazin-2,2-dione
[0226] LC: 92.3%. MS: m/z 434.1 (M+1). .sup.1H-NMR (CDCl.sub.3): d
1.95-2.30 (m, 6H), 3.10 (b, 2H), 3.65 (s, 2H), 4.10 (M, 1H), 4.50
(s, 2H), 7.10-7.70 (m, 13H).
1-[1-(10,11-Dihydro-5H-dibenzo[a,d]-cyclohepten-5-yl)-4-piperidinyl]-2,1,3-
-benzothiadiazin-2,2-dione
[0227] LC: 100%. MS: m/z 482.2. .sup.1H-NMR (DMSO): d 1.75 (b, 4H),
1.92 (m, 2H), 2.60-2.80 (m, 4H), 3.82 (m, 3H), 4.00 (s, 1H), 4.30
(s, 2H), 7.00-7.40 (M, 12H).
1-[1-(3,3-Bis(phenyl)propyl)-4-piperidinyl]-2,1,3-benzothiadiazin-2,2-dion-
e
[0228] LC: 100%. MS: m/z 461.7. .sup.1H-NMR (DMSO): d 1.75-2.00 (m,
6H), 2.17 (b, 4H), 2.82 (m, 2H), 3.85 (m, 1H), 3.95 (m, 1H), 4.35
(s, 2H), 7.05-7.20 (m, 5H), 7.22-7.35 (m, 9H).
1-[1-p-benzyloxybenzyl)-4-piperidinyl]-2,1,3-benzothiadiazin-2,2-dione
[0229] LC: 100%. MS: m/z 464 (M+1). .sup.1H-NMR (CDCl.sub.3): d
1.90 (m, 2H), 2.10 (m, 4H), 2.98 (m, 2H), 3.45 (s, 2H), 4.10 (m,
1H), 4.45 (s, 2H), 5.10 (s, 2H), 6.90 (d, 2H), 7.10-7.50 (m,
11H).
1-[1-(1,2,3,4-tetrahydronaphthyl)-4-piperidinyl]-2,1,3-benzothiadiazin-2,2-
-dione
[0230] LC: 100%. MS: m/z 398.5 (M+1). .sup.1H-NMR (MeOH-d.sub.4): d
1.75-3.45 (m, 14H), 3.60 (m, 1H), 4.30 (m, 1H), 4.50 (s, 2H),
7.10-7.40 (m, 8H).
1-[1-(4-propylcyclohexyl)-4-piperidinyl]-2,1,3-benzothiadiazin-2,2-dione
[0231] LC: 95.1%. MS: m/z 391.9. .sup.1H-NMR (CDCl.sub.3): d 0.90
(m, 4H), 1.20 (m, 1H), 1.30 (m, 5H), 1.60-1.95 (m, 6H), 2.00 (m,
2H), 2.17 (m, 2H), 2.30-2.50 (m, 3H), 3.20 (m, 2H), 4.10 (m, 1H),
4.50 (s, 2H), 7.15 (m, 2H), 7.23 (d, 1H), 7.35 (t, 1H).
1-[1-(5-methylhex-2-yl)-4-piperidinyl]-2,1,3-benzothiadiazin-2,2-dione
[0232] LC: 77.0%. MS: m/z 366.2 (M+1). .sup.1H-NMR (CDCl.sub.3): d
0.85 (d, 6H), 0.95 (d, 3H), 1.15-2.15 (m, 9H), 2.22-2.60 (m, 3H),
2.90 (m, 2H), 4.01 (m, 1H), 4.50 (s, 2H), 7.08-7.40 (m, 4H).
1-[1-(norbornan-2-yl)-4-piperidinyl]-2,1,3-benzothiadiazin-2,2-dione
[0233] LC: 100%. MS: m/z 362.6 (M+1). .sup.1H-NMR (CDCl.sub.3): d
1.10 (m, 1H), 1.40-1.75 (m, 6H), 2.05 (m, 1H), 2.15 (m, 2H),
2.30-2.55 (m, 3H), 2.60 (b, 1H), 2.80 (m, 2H), 3.10 (m, 1H), 3.51
(m, 2H), 4.25 (m, 1H), 4.50 (s, 2H), 7.20-7.40 (m, 4H).
1-[1-(decahydro-2-naphthyl)-4-piperidinyl]-2,1,3-benzothiadiazin-2,2-dione
[0234] LC: 100%. MS: m/z 404.2 (M+1). .sup.1H-NMR (DMSO): d
1.15-1.78 (m, 16H), 1.85 (m, 1H), 1.90-2.10 (m, 3H), 2.32 (m, 2H),
2.51 (m, 1H), 2.98 (m, 2H), 4.05 (m, 1H), 4.50 (s, 2H), 7.10-7.35
(m, 4H).
1-[1-(cyclooctyl)-4-piperidinyl]-2,1,3-benzothiadiazin-2,2-dione
[0235] LC: 96.0%. MS: m/z 378.5 (M+1). .sup.1H-NMR (MeOH): d
1.5-2.05 (m, 14H), 2.30 (m, 2H), 2.50 (m, 2H), 3.30 (m, 2H), 3.52
(m, 3H), 4.35 (m, 1H), 4.50 (s, 2H), 7.10-7.40 (m, 4H).
1-[1-[4-(2-propyl)-cyclohexyl]-4-piperidinyl]-2,1,3-benzothiadiazin-2,2-di-
one
[0236] LC: 100%. MS: m/z 392.2 (M+1). .sup.1H-NMR (CDCl.sub.3): d
0.90 (m, 5H), 1.12 (m, 1H), 1.25 (m, 2H), 1.47 (b, 2H), 1.65 (m,
2H), 1.80-2.00 (m, 3H), 2.18 (m, 3H), 2.54 (m, 2H), 3.08 (m, 3H),
3.50 (m, 2H), 4.29 (m, 1H), 4.53 (s, 2H), 7.10-7.30 (m, 3H), 7.40
(t, 1H).
1-[1-(1,3-dihydroinden-2-yl)-4-piperidinyl]-2,1,3-benzothiadiazin-2,2-dion-
e
[0237] LC: 100%. MS: m/z 384.3 (M+1). .sup.1H-NMR (DMSO): d
1.78-2.10 (m, 6H), 2.70 (m, 2H), 2.90-3.10 (m, 5H), 3.89 (m, 1H),
4.35 (s, 2H), 7.00-7.25 (m, 8H).
3-butyl-1-[1-[4-(2-propyl)-cyclohexyl]-4-piperidinyl]-2,1,3-benzothiadiazi-
n-2,2-dione
[0238] LC: 100%. MS: 448.4. H-NMR (DMSO): 7.35 t (1H); 7.11-7.23 m
(3H); 6.60 s (2H); 4.48 s (2H); 3.88-3.97 m (1H); 3.25 d (2H); 2.95
t (2H); 2.41 bs (1H); 2.25 bs (2H); 1.87 m (4H); 1.65 m (7H); 1.51
m (2H); 1.33 m (4H); 0.88 t (3H); 0.81 d (6H).
3-acetamido-1-[1-[4-(2-propyl)-cyclohexyl]-4-piperidinyl]-2,1,3-benzothiad-
iazin-2,2-dione
[0239] LC: 100%. MS: 449.2. H-NMR (CDCl.sub.3): 7.48 s (1H); 7.35 t
(1H); 7.25-7.33 m (3H); 6.55 s (2H); 4.51 s (2H); 3.90 m (1H); 3.56
s (2H); 3.18 d (2H); 2.45 bs (1H); 2.33 bs (2H); 1.75-1.95 m (4H);
1.50-1.68 m (6H); 1.44 m (1H); 1.33 m (1H); 1.12 m (1H); 0.78 d
(6H).
3-(2-methanesulfonamido)-1-[1-[4-(2-propyl)-cyclohexyl]-4-piperidinyl]-2,1-
,3-benzothiadiazin-2,2-dione
[0240] LC: 100%. MS: 513.2. H-NMR (DMSO): 7.09-7.30 m (4H); 6.58 s
(2H); 4.54 s (2H); 4.46 d (2H); 3.99 m (4H); 3.12 m (5H); 2.88 s
(3H); 2.33 bs (3H); 1.98 s (3H); 1.89 m (5H); 1.34 m (6H); 1.18 m
(4H); 1.16 t (2H); 0.82 d (6H).
3-methoxycarbonylmethyl-1-[1-[4-(2-propyl)-cyclohexyl]-4-piperidinyl]-2,1,-
3-benzothiadiazin-2,2-dione
[0241] LC: 100%. MS: 464.2. H-NMR (DMSO): 7.41 m (1H); 7.33 m (3H);
6.67 s (4H); 4.65 s (2H); 3.95 s (3H); 3.65 s (3H); 2.49 m (1H);
2.38 m (2H); 2.05 m (2H); 1.77 m (2H); 1.56 m (6H); 1.35 m (2H);
1.25 m (1H); 0.80 d (6H).
3-cyanomethyl-1-[1-[4-(2-propyl)-cyclohexyl]-4-piperidinyl]-2,1,3-benzothi-
adiazin-2,2-dione
[0242] LC: 100%. MS: 431.3. H-NMR (DMSO): 7.10-7.48 m (4H); 4.60 s
(2H); 4.45 s (2H); 3.77 m (1H); 2.91 d (2H); 2.25 m (1H); 1.90 t
(2H); 1.85 d (2H); 1.50-1.66 m (7H); 1.21-1.44 m (5H); 1.07 m (1H);
0.82 d (6H).
3-(2-hydroxyethyl)-1-[1-[4-(2-propyl)-cyclohexyl]-4-piperidinyl]-2,1,3-ben-
zothiadiazin-2,2-dione
[0243] LC: 100%. MS: 436.2. H-NMR (CDCl.sub.3): 7.38 t (1H); 7.22 m
(3H); 6.67 s (2H); 4.55 s (2H); 3.95 m (1H); 3.62 m (2H); 3.11 m
(4H); 2.44 bs (1H); 2.35 bs (2H); 1.85 bs (4H); 1.55-1.65 m (5H);
1.48 m (2H); 1.33 m (2H); 1.12 m (1H); 0.82 d (6H)
3-butoxycarbonylmethyl-1-[1-[4-(2-propyl)-cyclohexyl]-4-piperidinyl]-2,1,3-
-benzothiadiazin-2,2-dione
[0244] LC: 100%. MS: 506.2. H-NMR (DMSO): 7.31 m (1H); 7.22 m (3H);
4.50 s (2H); 3.71 s (3H); 2.90 d (2H); 2.22 m (1H); 1.98 t (2H);
1.80 d (2H); 1.50-1.70 m (4H); 1.44-1.58 m (12H); 1.28 m (5H); 1.01
m (1H) 0.81 d (6H)
[0245] Other compounds within the scope of formula (J) or (IA) of
the present invention can be synthesized by analogous
techniques.
Example 4
[0246] Nociceptin affinity at the ORL1 receptor for preferred
compounds was obtained using the following assay:
[0247] Membranes from recombinant HEK-293 cells expressing the
human opioid receptor-like receptor (ORL-1) (Receptor Biology) were
prepared by lysing cells in ice-cold hypotonic buffer (2.5 mM
MgCl.sub.2, 50 mM HEPES, pH 7.4) (10 ml/10 cm dish) followed by
homogenization with a tissue grinder/teflon pestle. Membranes were
collected by centrifugation at 30,000.times.g for 15 min at
4.degree. C. and pellets resuspended in hypotonic buffer to a final
concentration of 1-3 mg/ml. Protein concentrations were determined
using the BioRad protein assay reagent with bovine serum albumen as
standard. Aliquots of the ORL-1 receptor membranes were stored at
-80.degree. C.
[0248] Functional SGTPgS binding assays were conducted as follows.
ORL-1 membrane solution was prepared by sequentially adding final
concentrations of 0.066 mg/ml ORL-1 membrane protein, 10 mg/ml
saponin, 3 mM GDP and 0.20 nM [.sup.35S]GTPgS to binding buffer
(100 mM NaCl, 10 mM MgCl.sub.2, 20 mM HEPES, pH 7.4) on ice. The
prepared membrane solution (190 ml/well) was transferred to
96-shallow well polypropylene plates containing 10 ml of 20.times.
concentrated stock solutions of agonist prepared in DMSO. Plates
were incubated for 30 min at room temperature with shaking.
Reactions were terminated by rapid filtration onto 96-well
Unifilter GF/B filter plates (Packard) using a 96-well tissue
harvester (Brandel) and followed by three filtration washes with
200 ml ice-cold binding buffer (10 mM NaH.sub.2PO.sub.4, 10 mM
Na.sub.2HPO.sub.4, pH 7.4). Filter plates were subsequently dried
at 50.degree. C. for 2-3 hours. Fifty ml/well scintillation
cocktail (BetaScint; Wallac) was added and plates were counted in a
Packard Top-Count for 1 ml/well.
[0249] Data was analyzed using the curve fitting functions in
GraphPad PRISMO, v. 3.0 and the results are set forth in table 1
below:
TABLE-US-00001 TABLE 1 Nociceptin Affinity calc K.sub.i Compound
(nM) 1-1-[1-(naphth-2-yl-methyl)-4-piperidinyl]-2,1,3- >10,000
benzothiadiazin-2,2-dione;
1-1-[1-(p-phenylbenzyl)-4-piperidinyl]-2,1,3-benzothiadiazin-
>10,000 2,2-dione;
1-1-[1-(3,3-Bis(phenyl)propyl)-4-piperidinyl]-2,1,3- 4461
benzothiadiazin-2,2-dione;
1-1-[1-(p-benzyloxybenzyl)-4-piperidinyl]-2,1,3- 7114
benzothiadiazin-2,2-dione;
1-1-[1-(cyclooctylmethyl)-4-piperidinyl]-2,1,3-benzothiadiazin- 49
2,2-dione;
1-[1-(4-propylcyclohexyl)-4-piperidinyl]-2,1,3-benzothiadiazol-
5102 2,2-dione;
1-[1-(5-methylhex-2-yl)-4-piperidinyl]-2,1,3-benzothiadiazol- 3592
2,2-dione; 1-[1-[4-(2-propyl)-cyclohexyl]-4-piperidinyl]-2,1,3- 357
benzothiadiazol-2,2-dione;
1-[1-(1,2,3,4-tetrahydro-2-naphthyl)-4-piperidinyl]-2,1,3- 3454
benzothiadiazol-2,2-dione;
1-[1-(decahydro-2-naphthyl)-4-piperidinyl]-2,1,3- 225
benzothiadiazol-2,2-dione;
1-[1-(1,3,-dihydroinden-2-yl)-4-piperidinyl]-2,1,3- 5670
benzothiadiazol-2,2-dione;
1-[1-(cyclooctyl)-4-piperidinyl]-2,1,3-benzothiadiazol-2,2- 2297
dione;
1-[1-(naphth-2-yl-methyl)-4-piperidinyl]-2,1,3-benzothiadiazin- 609
2,2-dione
1-[1-(p-benzyloxybenzyl)-4-piperidinyl]-2,1,3-benzothiadiazin- 1878
2,2-dione
1-[1-(p-phenylbenzyl)-4-piperidinyl]-2,1,3-benzothiadiazin-2,2-
9535 dione 1-[1-(decahydro-2-naphthyl)-4-piperidinyl]-2,1,3- 28.7
benzothiadiazin-2,2-dione
1-[1-[4-(2-propyl)-cyclohexyl]-4-piperidinyl]-2,1,3- 35.3
benzothiadiazin-2,2-dione
1-1-[1-(4-propylcyclohexyl)-4-piperidinyl]-2,1,3- 231
benzothiadiazin-2,2-dione
1-1-[1-(benzyl)-4-piperidinyl]-2,1,3-benzothiadiazin-2,2-dione;
3900 1-1-[1-(10,11-Dihydro-5H-dibenzo [a,d]-cyclohepten-5-yl)-4-
505 piperidinyl]-2,1,3-benzothiadiazin-2,2-dione;
1-1-[1-(1,2,3,4-tetrahydronaphthyl)-4-piperidinyl]-2,1,3- 2614
benzothiadiazin-2,2-dione;
1-1-[1-(5-methylhex-2-yl)-4-piperidinyl]-2,1,3-benzothiadiazin- 40
2,2-dione;
1-1-[1-(norbornan-2-yl)-4-piperidinyl]-2,1,3-benzothiadiazin- 6329
2,2-dione;
1-1-[1-(cyclooctyl)-4-piperidinyl]-2,1,3-benzothiadiazin-2,2- 187
dione; 1-1-[1-(1,3-dihydroinden-2-yl)-4-piperidinyl]-2,1,3- 46
benzothiadiazin-2,2-dione.
1-[1-(3,3-Bis(phenyl)propyl)-4-piperidinyl]-2,1,3- 83
benzothiadiazin-2,2-dione
3-butyl-1-[1-[4-(2-propyl)-cyclohexyl]-4-piperidinyl]-2,1,3- 18
benzothiadiazin-2,2-dione
3-acetamido-1-[1-[4-(2-propyl)-cyclohexyl]-4-piperidinyl]- 3.9
2,1,3-benzothiadiazin-2,2-dione
3-(2-methanesulfonamido)-1-[1-[4-(2-propyl)-cyclohexyl]-4- 5
piperidinyl]-2,1,3-benzothiadiazin-2,2-dione
3-methoxycarbonylmethyl-1-[1-[4-(2-propyl)-cyclohexyl]-4- 41
piperidinyl]-2,1,3-benzothiadiazin-2,2-dione
3-cyanomethyl-1-[1-[4-(2-propyl)-cyclohexyl]-4-piperidinyl]- 33
2,1,3-benzothiadiazin-2,2-dione
3-(2-hydroxyethyl)-1-[1-[4-(2-propyl)-cyclohexyl]-4- 7.4
piperidinyl]-2,1,3-benzothiadiazin-2,2-dione
3-butoxycarbonylmethyl-1-[1-[4-(2-propyl)-cyclohexyl]-4- 63
piperidinyl]-2,1,3-benzothiadiazin-2,2-dione
Example 5
Synthesis of Quinoline Head Groups
##STR00016##
[0250] Procedure:
[0251] To a solution of 1 (5 g, 25.1 mmol) in 125 mL of MeOH at
room temperature was added NaBH.sub.4 (1.9 g, 50.2 mmol)
portionwise and the reaction mixture was stirred for 2 hr. The
mixture was evaporated to dryness and sat. NH.sub.4Cl solution was
added. The mixture was extracted with EtOAc (5.times.). The
combined organic extracts were dried over K.sub.2CO.sub.3, filtered
and evaporated under reduced pressure to give the crude product 2
as a white solid. This material was used directly in the next step
without further purification.
[0252] .sup.1H-NMR (CDCl.sub.3): d 1.40-1.55 (m, 11H), 1.85 (m,
2H), 3.00 (m, 2H), 3.85 (m, 3H).
[0253] To a solution of 2 (5.05 g, 25.1 mmol) in 50 mL of THF at
0.degree. C. was added Et.sub.3N (5.25 mL, 37.6 mmol) and
CH.sub.3SO.sub.2CJ (2.14 mL, 27.6 mmol). The reaction was stirred
at room temperature for 2 hr. The resulting mixture was diluted
with ether, washed with sat. NH.sub.4Cl solution (3.times.), dried
over MgSO.sub.4 and evaporated to give the crude product as a
solid. Trituration with hexane gave 3 as an off-white solid (6.30
g, 90% for two steps).
[0254] .sup.1H-NMR (CDCl.sub.3): d 1.45 (s, 9H), 1.80 (m, 2H), 1.95
(m, 2H), 3.02 (s, 3H), 3.30 (m, 2H), 3.72 (m, 2H), 4.90 (m,
1H).
[0255] To a solution of compound 4 (5.00 g, 34.0 mmol) in 500 mL of
xylene was added NaH (1.63 g, 40.8 mmol) at room temperature. After
the addition, the mixture was heated to reflux for 2 hr. After
cooling to room temperature 3 (11.39 g, 40.8 mmol) was added in one
portion. The reaction mixture was heated to gentle reflux and
maintained for 20 hr. The cooled solution was partitioned between
brine and EtOAc. The layers were separated and the aqueous layer
extracted with EtOAc (1.times.). The combined organic extracts were
dried over MgSO.sub.4, filtered and evaporated to give the crude 5
as an oil, which was used directly to the next step without
purification.
[0256] A mixture of concentrated HCl in EtOAc (150 ml, 1:10) was
added to compound 5 (11.2 g, 34.0 mmol) at room temperature. The
reaction was monitored by TLC. When the reaction was complete,
water and EtOAc were added, the layers separated and the aqueous
layer was washed with EtOAc (1.times.). The organic washings were
discarded and the aqueous layer was basified with K.sub.2CO.sub.3
and extracted with EtOAc (3.times.). The organic extracts were
dried over MgSO.sub.4, filtered and evaporated to give the crude
product that was purified by column chromatography to give 6 (4.30
g, 55% for 2 steps) as a clear glass.
[0257] .sup.1H-NMR (CDCl.sub.3): d 1.75 (m, 2H), 2.47-2.88 (m, 8H),
3.20 (m, 2H), 4.35 (m, 1H), 7.02 (m, 1H), 7.12-7.25 (m, 3H).
Example 6
Attachment of Tail Groups
[0258] Tail groups were attached to the quinoline head groups
according to the following procedures:
##STR00017##
General Procedure for Alkylation:
[0259] To a solution of the amine (1 eq) and triethylamine (1 eq)
in dimethylformamide, was added 1 eq of alkyl bromide or chloride
in one portion. The mixture was stirred and heated at 80.degree. C.
over night. TLC indicated the reaction was complete. The reaction
was quenched by the addition of water followed by 1 N NaOH to pH
10. The mixture was extracted 2.times. with Et.sub.2O. The combined
organic extracts were dried over potassium carbonate and the
solvent evaporated, followed by chromatography to give the pure
product.
General Procedure for Reductive Amination:
[0260] To a mixture of ketone or aldehyde (1 eq), amine (1 eq), and
acetic acid (1 eq) in methanol, was added sodium cyanoborohydride
(1.4 eq) in one portion. The mixture was stirred over night at room
temperature. TLC indicated the reaction was complete. The reaction
was quenched by the addition of water followed by 1 N NaOH to pH
10. The mixture was extracted 2.times. with Et.sub.2O. The combined
organic extracts were dried over potassium carbonate and the
solvent evaporated, followed by chromatography to give the pure
product.
[0261] The following compounds were prepared by attaching the tail
groups using the general procedures described:
1,2,3,4-tetrahydro-1-[1-(naphth-2-yl-methyl)-4-piperidinyl]-quinolin-2-one
[0262] LC: 97.4%. MS: m/z 371.2 (M+1). .sup.1H-NMR (CDCl.sub.3): d
1.70 (m, 2H), 2.20 (m, 2H), 2.55 (m, 2H), 2.68 (m, 2H), 2.82 (m,
2H), 3.05 (b, 2H), 3.70 (s, 2H), 4.32 (m, 1H), 7.02 (m, 1H), 7.15
(d, 1H), 7.20-7.30 (m, 2H), 7.42 (m, 2H), 7.51 (d, 1H), 7.75 (s,
1H), 7.85 (m, 3H).
1,2,3,4-tetrahydro-1-[1-(p-phenylbenzyl)-4-piperidinyl]-quinolin-2-one
[0263] LC: 100%. MS: 1-m/z 397.2 (M+1). .sup.1H-NMR (CDCl.sub.3): d
1.75 (b, 2H), 2.20 (m, 2H), 2.60 (m, 2H), 2.72 (m, 2H), 2.85 (m,
2H), 3.08 (b, 2H), 3.62 (s, 2H), 4.35 (m, 1H), 7.00-7.70 (m,
13H).
1,2,3,4-tetrahydro-1-[1-[4,4-bis(4-fluorophenyl)butyl]-4-piperidinyl]-quin-
olin-2-one
[0264] LC: 93.6%. MS: m/z 475.3 (M+1). .sup.1H-NMR (CDCl.sub.3): d
1.50 (m, 2H), 1.75 (m, 2H), 2.05 (m, 4H), 2.4 (m, 2H), 2.65 (m,
4H), 2.80 (m, 2H), 3.01 (m, 2H), 3.90 (t, 1H), 4.35 (m, 1H),
6.90-7.35 (m, 12H).
1,2,3,4-tetrahydro-1-[1-(p-benzyloxybenzyl)-4-piperidinyl]-quinolin-2-one
[0265] LC: 100%. MS: m/z 427.2 (M+1). .sup.1H-NMR (CDCl.sub.3): d
1.75 (m, 2H), 2.10 (m, 2H), 2.78-2.90 (m, 4H), 2.85 (m, 2H), 3.05
(m, 2H), 3.50 (s, 2H), 4.40 (m, 1H), 5.05 (s, 2H), 7.00-7.60 (m,
13H).
1,2,3,4-tetrahydro-1-[1-(1,2,3,4-tetrahydro-2-naphthyl)-4-piperidinyl]-qui-
nolin-2-one
[0266] LC: 98.8%. MS: m/z 361.2 (M+1). .sup.1H-NMR (CDCl.sub.3): d
1.88-2.12 (m, 3H), 2.45 (m, 1H), 2.65 (m, 2H), 2.80-2.35 (m, 8H),
3.50-3.75 (m, 3H), 3.90 (m, 2H), 4.80 (m, 1H), 7.05-7.55 (m,
8H).
1,2,3,4-tetrahydro-1-[1-(4-propyl-cyclohexyl)-4-piperidinyl]-quinolin-2-on-
e
[0267] LC: 100%. MS: m/z 355.2 (M+1). .sup.1H-NMR (CDCl.sub.3): d
0.80-2.25 (m, 18H), 3.55-3.70 (m, 2H), 2.85-3.30 (m, 6H), 3.45-3.80
(m, 4H), 7.00-7.50 (m, 4H).
1,2,3,4-tetrahydro-1-[1-(5-methylhex-2-yl)-4-piperidinyl]-quinolin-2-one
[0268] LC: 100%. MS: m/z 329.6 (M+1). .sup.1H-NMR (CDCl.sub.3): d
0.95 (m, 6H), 1.25-1.35 (m, 3H), 1.42 (d, 3H), 1.53-1.70 (m, 2H),
2.10 (m, 2H), 3.60 (m, 2H), 2.85-3.55 (m, 12H), 7.05-7.40 (m,
4H).
1,2,3,4-tetrahydro-1-[1-(norbornan-2-yl)-4-piperidinyl]-quinolin-2-one
[0269] LC: 100%. MS: m/z 325.2 (M+1). .sup.1H-NMR (CDCl.sub.3): d
1.22 (m, 1H), 1.40-1.65 (m, 5H), 1.80-2.10 (m, 5H), 2.30 (b, 1H),
2.50 (m, 2H), 2.61 (b, 1H), 2.85 (m, 2H), 2.90-3.20 (m, 4H), 3.50
(m, 2H), 4.45 (m, 1H), 7.02 (t, 1H), 7.22 (d, 1H), 7.28-7.40 (m,
2H).
1,2,3,4-tetrahydro-1-[1-(decahydro-2-naphthyl)-4-piperidinyl]-quinolin-2-o-
ne
[0270] LC: 100%. MS: m/z 367.2 (M+1). .sup.1H-NMR (CDCl.sub.3): d
1.20-2.15 (m, 12H), 3.63 (m, 2H), 2.85-3.75 (m, 14H), 4.25-4.45 (m,
2H), 7.05-7.45 (m, 4H).
1,2,3,4-tetrahydro-1-[1-(10,11-dihydro-5H-dibenzo[a.d]-cyclohepten-5-yl)-4-
-piperidinyl]-quinolin-2-one
[0271] LC: 100%. .sup.1H-NMR (CDCl.sub.3): d 1.62 (b, 2H), 2.00 (m,
2H), 2.51-2.70 (m, 4H), 3.85 (m, 6H), 4.00 (s, 1H), 4.05-4.25 (m,
3H), 7.00-7.30 (m, 12H).
1,2,3,4-tetrahydro-1-[1-(3,3-diphenylpropyl)-4-piperidinyl]-quinolin-2-one
[0272] LC: 99.3%. MS: m/z 425.3 (M+1). .sup.1H-NMR (CDCl.sub.3): d
1.70 (b, 2H), 2.05 (m, 2H), 2.30 (m, 4H), 2.55-2.70 (m, 4H), 2.80
(m, 2H), 3.02 (b, 2H), 4.02 (m, 1H), 4.30 (m, 1H), 7.00 (m, 1H),
7.12-7.35 (m, 13H).
1,2,3,4-tetrahydro-1-[1-(cyclooctyl)-4-piperidinyl]-quinolin-2-one
[0273] LC: 100%. MS: m/z 341.2 (M+1). .sup.1H-NMR (CDCl.sub.3): d
1.36-1.76 (m, 114H), 1.78-1.89 (m, 2H), 1.92-1.95 (m, 2H),
1.98-2.09 (m, 2H), 2.58-2.62 (m, 2H), 2.79-2.82 (m, 2H), 3.00-3.08
(m, 3H), 3.28-3.42 (m, 3H), 4.90-4.98 (m, 1H), 7.05 (t, 1H), 7.14
(d, 1H), 7.40 (d, 1H), 7.51 (t, 1H).
1,2,3,4-tetrahydro-1-[1-[4-(1-methylethyl)-cyclohexyl]-4-piperidinyl]-quin-
olin-2-one
[0274] LC: 100%. MS: m/z 355.2 (M+1). .sup.1H-NMR (CDCl.sub.3): d
0.90-1.05 (m, 6H), 1.05-2.30 (m, 13H), 2.60 (m, 2H), 2.80-3.80 (m,
6H), 4.35 (m, 2H), 4.55 (m, 1H), 7.05-7.45 (m, 4H).
1,2,3,4-tetrahydro-1-[1-(1,3-dihydroinden-2-yl)-4-piperidinyl]-quinolin-2--
one
[0275] LC: 90.4%. MS: m/z 347.2 (M+1). .sup.1H-NMR (CDCl.sub.3): d
1.90 (b, 2H), 2.60 (m, 2H), 2.70-3.00 (m, 6H), 3.25 (m, 4H), 3.40
(b, 2H), 3.80 (m, 1H), 4.70 (m, 1H), 7.00-7.40 (m, 8H).
1,2,3,4-tetrahydro-1-[1-(cyclooctylmethyl)-4-piperidinyl]-quinolin-2-one
[0276] LC: 100%. MS: m/z 355.3 (M+1). .sup.1H-NMR (CDCl.sub.3): d
1.15-1.28 (m, 2H), 1.39-1.78 (M, 15H), 1.98-2.10 (m, 4H), 2.51-2.68
(m, 4H), 2.79 (t, 2H), 2.98 (d, 2H), 4.21-4.31 (m, 1H), 6.95-7.01
(m, 1H), 7.11-7.14 (m, 1H), 7.20-7.24 (m, 2H).
[0277] Other compounds within the scope of formula (II) or (IIA) of
the present invention can be synthesized by analogous
techniques.
Example 7
[0278] Nociceptin affinity at the ORL1 receptor for preferred
compounds was obtained using the following assay:
[0279] Membranes from recombinant HEK-293 cells expressing the
human opioid receptor-like receptor (ORL-1) (Receptor Biology) were
prepared by lysing cells in ice-cold hypotonic buffer (2.5 mM
MgCl.sub.2, 50 mM HEPES, pH 7.4) (10 ml/10 cm dish) followed by
homogenization with a tissue grinder/teflon pestle. Membranes were
collected by centrifugation at 30,000.times.g for 15 min at
4.degree. C. and pellets resuspended in hypotonic buffer to a final
concentration of 1-3 mg/ml. Protein concentrations were determined
using the BioRad protein assay reagent with bovine serum albumen as
standard. Aliquots of the ORL-1 receptor membranes were stored at
-80.degree. C.
[0280] Functional SGTPgS binding assays were conducted as follows.
ORL-1 membrane solution was prepared by sequentially adding final
concentrations of 0.066 mg/ml ORL-1 membrane protein, 10 mg/ml
saponin, 3 mM GDP and 0.20 nM [.sup.35S]GTPgS to binding buffer
(100 mM NaCl, 10 mM MgCl.sub.2, 20 mM HEPES, pH 7.4) on ice. The
prepared membrane solution (190 ml/well) was transferred to
96-shallow well polypropylene plates containing 10 ml of 20.times.
concentrated stock solutions of agonist prepared in DMSO. Plates
were incubated for 30 min at room temperature with shaking.
Reactions were terminated by rapid filtration onto 96-well
Unifilter GF/B filter plates (Packard) using a 96-well tissue
harvester (Brandel) and followed by three filtration washes with
200 ml ice-cold binding buffer (10 mM NaH.sub.2PO.sub.4, 10 mM
Na.sub.2HPO.sub.4, pH 7.4). Filter plates were subsequently dried
at 50.degree. C. for 2-3 hours. Fifty ml/well scintillation
cocktail (BetaScint; Wallac) was added and plates were counted in a
Packard Top-Count for 1 min/well.
[0281] Data was analyzed using the curve fitting functions in
GraphPad PRISMO, v. 3.0 and the results are set forth in table 2
below:
TABLE-US-00002 TABLE 2 Nociceptin Affinity calc K.sub.i Compound
(nM) 1,2,3,4-tetrahydro-1-[1-(naphth-2-yl-methyl)-4-piperidinyl]-
3389 quinolin-2-one
1,2,3,4-tetrahydro-1-[1-(p-phenylbenzyl)-4-piperidinyl]- >10,000
quinolin-2-one
1,2,3,4-tetrahydro-1-[1-[4,4-bis(4-fluorophenyl)butyl]-4- 2898
piperidinyl]-quinolin-2-one
1,2,3,4-tetrahydro-1-[1-(p-benzyloxybenzyl)-4-piperidinyl]- 3502
quinolin-2-one
1,2,3,4-tetrahydro-1-[1-(1,2,3,4-tetrahydro-2-naphthyl)-4- 176
piperidinyl]-quinolin-2-one-
1,2,3,4-tetrahydro-1-[1-(4-propyl-cyclohexyl)-4-piperidinyl]- 1257
quinolin-2-one
1,2,3,4-tetrahydro-1-[1-(5-methylhex-2-yl)-4-piperidinyl]- 505
quinolin-2-one
1,2,3,4-tetrahydro-1-[1-(norbornan-2-yl)-4-piperidinyl]- 781
quinolin-2-one
1,2,3,4-tetrahydro-1-[1-(decahydro-2-naphthyl)-4-piperidinyl]- 105
quinolin-2-one
1,2,3,4-tetrahydro-1-[1-(10,11-dihydro-5H-dibenzo[a.d]- 95
cyclohepten-5-yl)-4-piperidinyl]-quinolin-2-one;
1,2,3,4-tetrahydro-1-[1-(3,3-diphenylpropyl)-4-piperidinyl]- 71
quinolin-2-one
1,2,3,4-tetrahydro-1-[1-[4-(1-methylethyl)-cyclohexyl]-4- 80
piperidinyl]-quinolin-2-one
1,2,3,4-tetrahydro-1-[1-(1,3-dihydroinden-2-yl)-4-piperidinyl]- 71
quinolin-2-one
1,2,3,4-tetrahydro-1-[1-(cyclooctyl)-4-piperidinyl]-quinolin-2- 14
one
Example 8
[0282] Affinity at the .mu. receptor for compounds was obtained
according to the following assay:
[0283] Mu opioid receptor membrane solution was prepared by
sequentially adding final concentrations of 0.075 .mu.g/.mu.l of
the desired membrane protein, 10 .mu.g/ml saponin, 3 .mu.M GDP and
0.20 nM [.sup.35S]GTP.gamma.S to binding buffer (100 mM NaCl, 10 mM
MgCl.sub.2, 20 mM HEPES, pH 7.4) on ice. The prepared membrane
solution (190 .mu.l/well) was transferred to 96-shallow well
polypropylene plates containing 10 .mu.l of 20.times. concentrated
stock solutions of agonist prepared in DMSO. Plates were incubated
for 30 min at room temperature with shaking. Reactions were
terminated by rapid filtration onto 96-well Unifilter GF/B filter
plates (Packard) using a 96-well tissue harvester (Brandel) and
followed by three filtration washes with 200 .mu.l ice-cold binding
buffer (10 mM NaH.sub.2PO.sub.4, 10 mM Na.sub.2HPO.sub.4, pH 7.4).
Filter plates were subsequently dried at 50.degree. C. for 2-3
hours. Fifty .mu.l/well scintillation cocktail (MicroScint20,
Packard) was added and plates were counted in a Packard Top-Count
for 1 min/well.
[0284] Data were analyzed using the curve fitting functions in
GraphPad PRISM.TM., v. 3.0 and the results of several compounds are
set forth in table 3 below:
TABLE-US-00003 TABLE 3 Mu Receptor Affinity calc K.sub.i Compound
(nM) 1-[1-(decahydro-2-naphthyl)-4-piperidinyl]-2,1,3- 91.7
benzothiadiazin-2,2-dione
1-[1-[4-(2-propyl)-cyclohexyl]-4-piperidinyl]-2,1,3- 207
benzothiadiazin-2,2-dione
1-1-[1-(cyclooctyl)-4-piperidinyl]-2,1,3-benzothiadiazin-2,2- 1376
dione; 1-1-[1-(1,3-dihydroinden-2-yl)-4-piperidinyl]-2,1,3- 660
benzothiadiazin-2,2-dione.
1,2,3,4-tetrahydro-1-[1-(cyclooctyl)-4-piperidinyl]-quinolin-2- 86
one; 1,2,3,4-tetrahydro-1-[1-(5-methylhex-2-yl)-4-piperidinyl]- 156
quinolin-2-one
1,2,3,4-tetrahydro-1-[1-(norbornan-2-yl)-4-piperidinyl]- 957
quinolin-2-one
1,2,3,4-tetrahydro-1-[1-(decahydro-2-naphthyl)-4-piperidinyl]- 341
quinolin-2-one
* * * * *